_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,direction,b1,b2,direction_gold,e1,e2,relation,relex_relcos,sent_id,sentence,term1,term2,twrex
503460422,7/16/2014 13:07:34,,1324244333,7/16/2014 13:07:18,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,117,71,,128,95,treats,1,907445-FS1-2,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D,RO-may_prevent
503460422,7/16/2014 13:26:30,,1324252000,7/16/2014 13:26:04,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,117,71,,128,95,treats,1,907445-FS1-2,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D,RO-may_prevent
503460422,7/16/2014 15:00:43,,1324288251,7/16/2014 15:00:11,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,117,71,,128,95,treats,1,907445-FS1-2,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D,RO-may_prevent
503460422,7/16/2014 15:41:25,,1324302587,7/16/2014 15:40:41,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,117,71,,128,95,treats,1,907445-FS1-2,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D,RO-may_prevent
503460422,7/16/2014 17:21:08,,1324344691,7/16/2014 17:20:30,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,117,71,,128,95,treats,1,907445-FS1-2,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D,RO-may_prevent
503460422,7/16/2014 18:23:00,,1324399223,7/16/2014 18:22:47,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,ACTIVE FORM OF VITAMIN D treats OSTEOPOROSIS,117,71,,128,95,treats,1,907445-FS1-2,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D,RO-may_prevent
503460422,7/16/2014 18:34:40,,1324404351,7/16/2014 18:34:31,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,117,71,,128,95,treats,1,907445-FS1-2,Some misunderstandings exist internationally about the efficacy of the ACTIVE FORM OF VITAMIN D for the treatment of OSTEOPOROSIS,OSTEOPOROSIS,ACTIVE FORM OF VITAMIN D,RO-may_prevent
503460423,7/16/2014 13:11:49,,1324246021,7/16/2014 13:11:38,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,PEMPHIGUS VULGARIS is location of DISEASE OF THE SKIN AND MUCOUS MEMBRANES,47,0,,86,18,is location of,0.800640769025436,902397-FS1-9,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460423,7/16/2014 13:33:20,,1324255058,7/16/2014 13:32:41,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,no_relation,47,0,,86,18,is location of,0.800640769025436,902397-FS1-9,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460423,7/16/2014 14:42:53,,1324282454,7/16/2014 14:42:18,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,no_relation,47,0,,86,18,is location of,0.800640769025436,902397-FS1-9,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460423,7/16/2014 15:01:18,,1324288448,7/16/2014 15:00:44,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,PEMPHIGUS VULGARIS is location of DISEASE OF THE SKIN AND MUCOUS MEMBRANES,47,0,,86,18,is location of,0.800640769025436,902397-FS1-9,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460423,7/16/2014 15:48:34,,1324305626,7/16/2014 15:48:22,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,47,0,,86,18,is location of,0.800640769025436,902397-FS1-9,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460423,7/16/2014 16:56:11,,1324336776,7/16/2014 16:55:13,instagc,0.6306,14941596,USA,KY,Erlanger,74.140.124.145,no_relation,47,0,,86,18,is location of,0.800640769025436,902397-FS1-9,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460423,7/16/2014 17:28:40,,1324348328,7/16/2014 17:28:14,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,DISEASE OF THE SKIN AND MUCOUS MEMBRANES is location of PEMPHIGUS VULGARIS,47,0,,86,18,is location of,0.800640769025436,902397-FS1-9,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460424,7/16/2014 13:10:48,,1324245660,7/16/2014 13:10:38,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,SYPHILIS treats ERYTHROMYCIN,41,0,,48,12,treats,0.963086824686154,907476-FS1-2,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN,RO-may_treat
503460424,7/16/2014 13:13:06,,1324246568,7/16/2014 13:12:26,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,no_relation,41,0,,48,12,treats,0.963086824686154,907476-FS1-2,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN,RO-may_treat
503460424,7/16/2014 13:30:14,,1324253586,7/16/2014 13:29:08,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,ERYTHROMYCIN treats SYPHILIS,41,0,,48,12,treats,0.963086824686154,907476-FS1-2,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN,RO-may_treat
503460424,7/16/2014 13:32:56,,1324254844,7/16/2014 13:31:54,inboxpounds,0.65,22207998,GBR,N7,Banstead,86.3.88.5,ERYTHROMYCIN treats SYPHILIS,41,0,,48,12,treats,0.963086824686154,907476-FS1-2,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN,RO-may_treat
503460424,7/16/2014 15:09:47,,1324291899,7/16/2014 15:09:42,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,ERYTHROMYCIN treats SYPHILIS,41,0,,48,12,treats,0.963086824686154,907476-FS1-2,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN,RO-may_treat
503460424,7/16/2014 15:39:35,,1324301791,7/16/2014 15:39:21,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,no_relation,41,0,,48,12,treats,0.963086824686154,907476-FS1-2,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN,RO-may_treat
503460424,7/16/2014 15:49:30,,1324305999,7/16/2014 15:49:09,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,41,0,,48,12,treats,0.963086824686154,907476-FS1-2,ERYTHROMYCIN failure in the treatment of SYPHILIS in a pregnant woman.,SYPHILIS,ERYTHROMYCIN,RO-may_treat
503460425,7/16/2014 13:16:44,,1324248052,7/16/2014 13:16:10,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,BCL 2 GENE is location of FOLLICULAR LYMPHOMAS,230,207,,249,217,is location of,0.617213399848368,906095-FS1-9,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460425,7/16/2014 13:19:39,,1324249173,7/16/2014 13:19:25,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,FOLLICULAR LYMPHOMAS is location of BCL 2 GENE,230,207,,249,217,is location of,0.617213399848368,906095-FS1-9,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460425,7/16/2014 13:24:47,,1324251211,7/16/2014 13:24:13,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,FOLLICULAR LYMPHOMAS is location of BCL 2 GENE,230,207,,249,217,is location of,0.617213399848368,906095-FS1-9,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460425,7/16/2014 13:27:24,,1324252435,7/16/2014 13:26:51,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,no_relation,230,207,,249,217,is location of,0.617213399848368,906095-FS1-9,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460425,7/16/2014 13:32:17,,1324254619,7/16/2014 13:31:33,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,BCL 2 GENE is location of FOLLICULAR LYMPHOMAS,230,207,,249,217,is location of,0.617213399848368,906095-FS1-9,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460425,7/16/2014 13:35:30,,1324256005,7/16/2014 13:34:54,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,BCL 2 GENE is location of FOLLICULAR LYMPHOMAS,230,207,,249,217,is location of,0.617213399848368,906095-FS1-9,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460425,7/16/2014 14:17:04,,1324272332,7/16/2014 14:16:43,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,FOLLICULAR LYMPHOMAS is location of BCL 2 GENE,230,207,,249,217,is location of,0.617213399848368,906095-FS1-9,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460426,7/16/2014 13:06:44,,1324244029,7/16/2014 13:06:25,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,50,134,,75,146,causes,0.722315118514615,901860-FS1-4,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503460426,7/16/2014 14:18:43,,1324273033,7/16/2014 14:18:25,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,50,134,,75,146,causes,0.722315118514615,901860-FS1-4,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503460426,7/16/2014 16:53:33,,1324335889,7/16/2014 16:52:49,clixsense,0.4786,6497991,USA,NC,Clinton,204.211.52.144,COMPLICATIONS OF PREGNANCY causes PREECLAMPSIA,50,134,,75,146,causes,0.722315118514615,901860-FS1-4,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503460426,7/16/2014 18:01:51,,1324379689,7/16/2014 18:01:29,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,50,134,,75,146,causes,0.722315118514615,901860-FS1-4,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503460426,7/16/2014 18:22:19,,1324398974,7/16/2014 18:22:03,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,no_relation,50,134,,75,146,causes,0.722315118514615,901860-FS1-4,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503460426,7/16/2014 18:47:19,,1324410909,7/16/2014 18:46:44,eup_slw,0.5873,28186528,USA,IN,Bloomington,74.204.124.9,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,50,134,,75,146,causes,0.722315118514615,901860-FS1-4,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503460426,7/16/2014 19:29:04,,1324434075,7/16/2014 19:28:24,clixsense,0.5333,6714657,USA,CT,Groton,71.235.184.32,PREECLAMPSIA causes COMPLICATIONS OF PREGNANCY,50,134,,75,146,causes,0.722315118514615,901860-FS1-4,"This article examines the recurrence risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA",COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,RO-disease_has_finding
503460427,7/16/2014 13:08:38,,1324244803,7/16/2014 13:08:10,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,HYPERSENSITIVITY contraindicates ALLERGY,102,182,,117,189,contraindicates,0.437594974493684,900315-FS1-10,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460427,7/16/2014 13:09:17,,1324245031,7/16/2014 13:08:55,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,HYPERSENSITIVITY contraindicates ALLERGY,102,182,,117,189,contraindicates,0.437594974493684,900315-FS1-10,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460427,7/16/2014 13:15:51,,1324247696,7/16/2014 13:15:34,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,HYPERSENSITIVITY contraindicates ALLERGY,102,182,,117,189,contraindicates,0.437594974493684,900315-FS1-10,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460427,7/16/2014 13:17:08,,1324248161,7/16/2014 13:16:45,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,no_relation,102,182,,117,189,contraindicates,0.437594974493684,900315-FS1-10,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460427,7/16/2014 13:21:51,,1324250079,7/16/2014 13:21:39,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,no_relation,102,182,,117,189,contraindicates,0.437594974493684,900315-FS1-10,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460427,7/16/2014 13:24:47,,1324251210,7/16/2014 13:24:13,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,no_relation,102,182,,117,189,contraindicates,0.437594974493684,900315-FS1-10,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460427,7/16/2014 17:04:16,,1324339466,7/16/2014 17:03:58,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,ALLERGY contraindicates HYPERSENSITIVITY,102,182,,117,189,contraindicates,0.437594974493684,900315-FS1-10,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460428,7/16/2014 13:22:23,,1324250288,7/16/2014 13:22:13,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,QUININE SULPHATE treats MUSCLE CRAMPS,57,89,,69,105,treats,0.991836598134176,907060-FS1-2,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE,RO-may_prevent
503460428,7/16/2014 13:24:19,,1324251004,7/16/2014 13:23:56,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,QUININE SULPHATE treats MUSCLE CRAMPS,57,89,,69,105,treats,0.991836598134176,907060-FS1-2,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE,RO-may_prevent
503460428,7/16/2014 13:27:24,,1324252434,7/16/2014 13:26:51,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,QUININE SULPHATE treats MUSCLE CRAMPS,57,89,,69,105,treats,0.991836598134176,907060-FS1-2,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE,RO-may_prevent
503460428,7/16/2014 14:21:26,,1324274137,7/16/2014 14:20:34,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,QUININE SULPHATE treats MUSCLE CRAMPS,57,89,,69,105,treats,0.991836598134176,907060-FS1-2,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE,RO-may_prevent
503460428,7/16/2014 15:34:34,,1324299857,7/16/2014 15:34:18,instagc,0.7538,19636746,USA,NY,Andover,192.182.216.225,QUININE SULPHATE treats MUSCLE CRAMPS,57,89,,69,105,treats,0.991836598134176,907060-FS1-2,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE,RO-may_prevent
503460428,7/16/2014 15:36:09,,1324300393,7/16/2014 15:35:58,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,QUININE SULPHATE treats MUSCLE CRAMPS,57,89,,69,105,treats,0.991836598134176,907060-FS1-2,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE,RO-may_prevent
503460428,7/16/2014 15:43:52,,1324303638,7/16/2014 15:43:37,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,QUININE SULPHATE treats MUSCLE CRAMPS,57,89,,69,105,treats,0.991836598134176,907060-FS1-2,Nine patients on maintenance haemodialysis with frequent MUSCLE CRAMPS were given 320 mg QUININE SULPHATE or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,MUSCLE CRAMPS,QUININE SULPHATE,RO-may_prevent
503460429,7/16/2014 13:20:13,,1324249412,7/16/2014 13:20:05,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,SCHIZOPHRENIA treats RISPERIDONE,104,0,,116,11,treats,0.911684611677103,907998-FS1-2,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460429,7/16/2014 13:22:21,,1324250287,7/16/2014 13:22:00,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,RISPERIDONE treats SCHIZOPHRENIA,104,0,,116,11,treats,0.911684611677103,907998-FS1-2,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460429,7/16/2014 13:38:24,,1324257028,7/16/2014 13:38:01,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,RISPERIDONE treats SCHIZOPHRENIA,104,0,,116,11,treats,0.911684611677103,907998-FS1-2,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460429,7/16/2014 15:10:01,,1324291969,7/16/2014 15:09:55,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,RISPERIDONE treats SCHIZOPHRENIA,104,0,,116,11,treats,0.911684611677103,907998-FS1-2,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460429,7/16/2014 15:13:27,,1324293086,7/16/2014 15:12:46,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,RISPERIDONE treats SCHIZOPHRENIA,104,0,,116,11,treats,0.911684611677103,907998-FS1-2,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460429,7/16/2014 17:06:15,,1324339980,7/16/2014 17:05:50,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,RISPERIDONE treats SCHIZOPHRENIA,104,0,,116,11,treats,0.911684611677103,907998-FS1-2,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460429,7/16/2014 17:17:09,,1324343588,7/16/2014 17:16:52,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,RISPERIDONE treats SCHIZOPHRENIA,104,0,,116,11,treats,0.911684611677103,907998-FS1-2,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460430,7/16/2014 13:08:45,,1324244870,7/16/2014 13:08:22,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,HEPATOMA causes ASCITES,75,52,,81,60,causes,0.583459965991578,902970-FS1-4,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460430,7/16/2014 13:09:08,,1324244975,7/16/2014 13:08:40,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,HEPATOMA causes ASCITES,75,52,,81,60,causes,0.583459965991578,902970-FS1-4,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460430,7/16/2014 13:14:31,,1324247212,7/16/2014 13:14:16,instagc,0.7083,18960682,GBR,"","",86.29.147.112,ASCITES causes HEPATOMA,75,52,,81,60,causes,0.583459965991578,902970-FS1-4,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460430,7/16/2014 13:21:25,,1324249873,7/16/2014 13:21:14,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,no_relation,75,52,,81,60,causes,0.583459965991578,902970-FS1-4,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460430,7/16/2014 14:27:05,,1324276301,7/16/2014 14:26:23,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,HEPATOMA causes ASCITES,75,52,,81,60,causes,0.583459965991578,902970-FS1-4,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460430,7/16/2014 14:36:30,,1324280355,7/16/2014 14:35:27,vivatic,0.4524,19526833,GBR,K2,Oxford,86.24.196.187,no_relation,75,52,,81,60,causes,0.583459965991578,902970-FS1-4,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460430,7/16/2014 14:55:44,,1324286312,7/16/2014 14:55:12,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,no_relation,75,52,,81,60,causes,0.583459965991578,902970-FS1-4,In 2 cases of fulminant hepatitis with sepsis and 3 HEPATOMA patients with ASCITES elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460431,7/16/2014 13:11:49,,1324246022,7/16/2014 13:11:38,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,no_relation,86,62,,113,81,treats,0.979957887012223,907492-FS1-2,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY,RO-may_treat
503460431,7/16/2014 13:22:42,,1324250372,7/16/2014 13:22:14,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,FLUDARABINE THERAPY treats CHRONIC LYMPHOCYTIC LEUKEMIA,86,62,,113,81,treats,0.979957887012223,907492-FS1-2,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY,RO-may_treat
503460431,7/16/2014 14:53:56,,1324285677,7/16/2014 14:53:38,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,FLUDARABINE THERAPY treats CHRONIC LYMPHOCYTIC LEUKEMIA,86,62,,113,81,treats,0.979957887012223,907492-FS1-2,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY,RO-may_treat
503460431,7/16/2014 16:55:15,,1324336443,7/16/2014 16:54:24,clixsense,0.4786,6497991,USA,NC,Clinton,204.211.52.144,no_relation,86,62,,113,81,treats,0.979957887012223,907492-FS1-2,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY,RO-may_treat
503460431,7/16/2014 18:07:27,,1324385395,7/16/2014 18:07:05,clixsense,0.4083,6451515,USA,MN,Minneapolis,75.144.36.177,CHRONIC LYMPHOCYTIC LEUKEMIA treats FLUDARABINE THERAPY,86,62,,113,81,treats,0.979957887012223,907492-FS1-2,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY,RO-may_treat
503460431,7/16/2014 18:22:46,,1324399109,7/16/2014 18:22:37,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,FLUDARABINE THERAPY treats CHRONIC LYMPHOCYTIC LEUKEMIA,86,62,,113,81,treats,0.979957887012223,907492-FS1-2,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY,RO-may_treat
503460431,7/16/2014 18:34:30,,1324404278,7/16/2014 18:34:24,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,86,62,,113,81,treats,0.979957887012223,907492-FS1-2,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after FLUDARABINE THERAPY for CHRONIC LYMPHOCYTIC LEUKEMIA",CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE THERAPY,RO-may_treat
503460432,7/16/2014 13:06:04,,1324243783,7/16/2014 13:05:50,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,PROSTATES is location of PROSTATIC CARCINOMAS,124,80,,132,100,is location of,0.979957887012223,902355-FS1-9,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS,RO-disease_has_primary_anatomic_site
503460432,7/16/2014 13:19:05,,1324248949,7/16/2014 13:18:59,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,PROSTATES is location of PROSTATIC CARCINOMAS,124,80,,132,100,is location of,0.979957887012223,902355-FS1-9,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS,RO-disease_has_primary_anatomic_site
503460432,7/16/2014 13:19:42,,1324249202,7/16/2014 13:19:35,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,PROSTATIC CARCINOMAS is location of PROSTATES,124,80,,132,100,is location of,0.979957887012223,902355-FS1-9,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS,RO-disease_has_primary_anatomic_site
503460432,7/16/2014 14:17:57,,1324272696,7/16/2014 14:17:28,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,PROSTATES is location of PROSTATIC CARCINOMAS,124,80,,132,100,is location of,0.979957887012223,902355-FS1-9,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS,RO-disease_has_primary_anatomic_site
503460432,7/16/2014 15:44:41,,1324303994,7/16/2014 15:44:19,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,PROSTATES is location of PROSTATIC CARCINOMAS,124,80,,132,100,is location of,0.979957887012223,902355-FS1-9,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS,RO-disease_has_primary_anatomic_site
503460432,7/16/2014 18:22:19,,1324398973,7/16/2014 18:22:03,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,PROSTATES is location of PROSTATIC CARCINOMAS,124,80,,132,100,is location of,0.979957887012223,902355-FS1-9,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS,RO-disease_has_primary_anatomic_site
503460432,7/16/2014 18:34:51,,1324404444,7/16/2014 18:34:41,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,124,80,,132,100,is location of,0.979957887012223,902355-FS1-9,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 PROSTATIC CARCINOMAS in surgically resected PROSTATES by PCR technique using consensus and type specific primers.,PROSTATES,PROSTATIC CARCINOMAS,RO-disease_has_primary_anatomic_site
503460433,7/16/2014 13:15:51,,1324247699,7/16/2014 13:15:34,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,57,31,,105,41,treats,0.995893206467704,907609-FS1-2,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL,RO-may_treat
503460433,7/16/2014 13:20:52,,1324249680,7/16/2014 13:20:33,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,57,31,,105,41,treats,0.995893206467704,907609-FS1-2,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL,RO-may_treat
503460433,7/16/2014 13:27:26,,1324252444,7/16/2014 13:26:48,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,57,31,,105,41,treats,0.995893206467704,907609-FS1-2,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL,RO-may_treat
503460433,7/16/2014 13:33:56,,1324255333,7/16/2014 13:32:57,inboxpounds,0.65,22207998,GBR,N7,Banstead,86.3.88.5,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,57,31,,105,41,treats,0.995893206467704,907609-FS1-2,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL,RO-may_treat
503460433,7/16/2014 14:21:47,,1324274289,7/16/2014 14:21:27,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,57,31,,105,41,treats,0.995893206467704,907609-FS1-2,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL,RO-may_treat
503460433,7/16/2014 14:53:37,,1324285576,7/16/2014 14:53:00,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,COLESTIPOL treats SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,57,31,,105,41,treats,0.995893206467704,907609-FS1-2,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL,RO-may_treat
503460433,7/16/2014 16:39:06,,1324330155,7/16/2014 16:38:57,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA treats COLESTIPOL,57,31,,105,41,treats,0.995893206467704,907609-FS1-2,Illingworth DR. Mevinolin plus COLESTIPOL in therapy for SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,SEVERE HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA,COLESTIPOL,RO-may_treat
503460434,7/16/2014 13:22:03,,1324250158,7/16/2014 13:21:53,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,ONCOGENIC OSTEOMALACIA causes PHOSPHATURIA,54,0,,65,22,causes,0.983078304622849,901839-FS1-4,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,RO-disease_has_finding
503460434,7/16/2014 13:38:00,,1324256867,7/16/2014 13:37:36,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,no_relation,54,0,,65,22,causes,0.983078304622849,901839-FS1-4,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,RO-disease_has_finding
503460434,7/16/2014 14:18:23,,1324272899,7/16/2014 14:17:58,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,no_relation,54,0,,65,22,causes,0.983078304622849,901839-FS1-4,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,RO-disease_has_finding
503460434,7/16/2014 16:57:26,,1324337243,7/16/2014 16:56:54,instagc,0.6306,14941596,USA,KY,Erlanger,74.140.124.145,PHOSPHATURIA causes ONCOGENIC OSTEOMALACIA,54,0,,65,22,causes,0.983078304622849,901839-FS1-4,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,RO-disease_has_finding
503460434,7/16/2014 17:17:31,,1324343694,7/16/2014 17:17:10,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,ONCOGENIC OSTEOMALACIA causes PHOSPHATURIA,54,0,,65,22,causes,0.983078304622849,901839-FS1-4,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,RO-disease_has_finding
503460434,7/16/2014 18:23:00,,1324399222,7/16/2014 18:22:47,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,no_relation,54,0,,65,22,causes,0.983078304622849,901839-FS1-4,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,RO-disease_has_finding
503460434,7/16/2014 18:34:23,,1324404224,7/16/2014 18:34:13,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,ONCOGENIC OSTEOMALACIA causes PHOSPHATURIA,54,0,,65,22,causes,0.983078304622849,901839-FS1-4,"ONCOGENIC OSTEOMALACIA is a syndrome characterized by PHOSPHATURIA hypophosphatemia, reduced vitamin D levels, and osteomalacia.",PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,RO-disease_has_finding
503460435,7/16/2014 13:07:33,,1324244320,7/16/2014 13:07:15,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,HAEMOPHILIA A treats HUMAN FACTOR VIII (FVIII),0,36,,12,61,treats,0.98058067569092,908174-FS1-2,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII),RO-may_treat
503460435,7/16/2014 13:08:38,,1324244824,7/16/2014 13:08:10,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,HAEMOPHILIA A treats HUMAN FACTOR VIII (FVIII),0,36,,12,61,treats,0.98058067569092,908174-FS1-2,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII),RO-may_treat
503460435,7/16/2014 14:26:55,,1324276223,7/16/2014 14:26:29,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,HAEMOPHILIA A treats HUMAN FACTOR VIII (FVIII),0,36,,12,61,treats,0.98058067569092,908174-FS1-2,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII),RO-may_treat
503460435,7/16/2014 16:40:10,,1324330758,7/16/2014 16:39:49,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,HUMAN FACTOR VIII (FVIII) treats HAEMOPHILIA A,0,36,,12,61,treats,0.98058067569092,908174-FS1-2,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII),RO-may_treat
503460435,7/16/2014 18:02:11,,1324380033,7/16/2014 18:01:51,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,HUMAN FACTOR VIII (FVIII) treats HAEMOPHILIA A,0,36,,12,61,treats,0.98058067569092,908174-FS1-2,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII),RO-may_treat
503460435,7/16/2014 18:07:27,,1324385391,7/16/2014 18:07:05,clixsense,0.4083,6451515,USA,MN,Minneapolis,75.144.36.177,HUMAN FACTOR VIII (FVIII) treats HAEMOPHILIA A,0,36,,12,61,treats,0.98058067569092,908174-FS1-2,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII),RO-may_treat
503460435,7/16/2014 18:22:46,,1324399110,7/16/2014 18:22:37,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,HUMAN FACTOR VIII (FVIII) treats HAEMOPHILIA A,0,36,,12,61,treats,0.98058067569092,908174-FS1-2,HAEMOPHILIA A patients treated with HUMAN FACTOR VIII (FVIII) may develop antibody (Ab) inhibitors to fVIII.,HAEMOPHILIA A,HUMAN FACTOR VIII (FVIII),RO-may_treat
503460436,7/16/2014 13:20:13,,1324249407,7/16/2014 13:20:05,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,FISTULA TRACT is location of CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,117,18,,129,74,is location of,0.949425326555083,906096-FS1-9,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,RO-has_manifestation
503460436,7/16/2014 15:09:54,,1324291944,7/16/2014 15:09:48,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL is location of FISTULA TRACT,117,18,,129,74,is location of,0.949425326555083,906096-FS1-9,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,RO-has_manifestation
503460436,7/16/2014 17:45:09,,1324362104,7/16/2014 17:44:41,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,FISTULA TRACT is location of CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,117,18,,129,74,is location of,0.949425326555083,906096-FS1-9,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,RO-has_manifestation
503460436,7/16/2014 17:59:26,,1324377278,7/16/2014 17:58:50,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,FISTULA TRACT is location of CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,117,18,,129,74,is location of,0.949425326555083,906096-FS1-9,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,RO-has_manifestation
503460436,7/16/2014 18:23:43,,1324399459,7/16/2014 18:23:21,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,FISTULA TRACT is location of CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,117,18,,129,74,is location of,0.949425326555083,906096-FS1-9,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,RO-has_manifestation
503460436,7/16/2014 18:34:02,,1324404057,7/16/2014 18:33:49,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,117,18,,129,74,is location of,0.949425326555083,906096-FS1-9,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,RO-has_manifestation
503460436,7/16/2014 18:47:19,,1324410908,7/16/2014 18:46:44,eup_slw,0.5873,28186528,USA,IN,Bloomington,74.204.124.9,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL is location of FISTULA TRACT,117,18,,129,74,is location of,0.949425326555083,906096-FS1-9,We here present a CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL fistula and the successful closure of the FISTULA TRACT with the novel liquid polymer sealant Onyx.,FISTULA TRACT,CASE OF SEVERE CROHN'S DISEASE WITH AN ESOPHAGOBRONCHIAL,RO-has_manifestation
503460437,7/16/2014 13:13:06,,1324246569,7/16/2014 13:12:26,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,VITILIGO is location of SKIN,562,534,,565,542,is location of,0.942809041582064,902476-FS1-9,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO,RO-disease_has_primary_anatomic_site
503460437,7/16/2014 13:19:57,,1324249301,7/16/2014 13:19:50,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,VITILIGO is location of SKIN,562,534,,565,542,is location of,0.942809041582064,902476-FS1-9,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO,RO-disease_has_primary_anatomic_site
503460437,7/16/2014 13:23:29,,1324250632,7/16/2014 13:22:43,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,SKIN is location of VITILIGO,562,534,,565,542,is location of,0.942809041582064,902476-FS1-9,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO,RO-disease_has_primary_anatomic_site
503460437,7/16/2014 13:34:22,,1324255524,7/16/2014 13:33:57,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,SKIN is location of VITILIGO,562,534,,565,542,is location of,0.942809041582064,902476-FS1-9,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO,RO-disease_has_primary_anatomic_site
503460437,7/16/2014 14:27:05,,1324276302,7/16/2014 14:26:23,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,no_relation,562,534,,565,542,is location of,0.942809041582064,902476-FS1-9,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO,RO-disease_has_primary_anatomic_site
503460437,7/16/2014 14:44:19,,1324282833,7/16/2014 14:43:50,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,VITILIGO is location of SKIN,562,534,,565,542,is location of,0.942809041582064,902476-FS1-9,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO,RO-disease_has_primary_anatomic_site
503460437,7/16/2014 15:42:50,,1324303128,7/16/2014 15:42:22,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,SKIN is location of VITILIGO,562,534,,565,542,is location of,0.942809041582064,902476-FS1-9,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between VITILIGO patches and normal SKIN.",SKIN,VITILIGO,RO-disease_has_primary_anatomic_site
503460438,7/16/2014 13:31:29,,1324254202,7/16/2014 13:30:49,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,ERYTHROMYCIN treats PERTUSSIS,95,110,,103,122,treats,0.987878339907213,907514-FS1-2,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN,RO-may_treat
503460438,7/16/2014 13:35:46,,1324256064,7/16/2014 13:35:32,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,ERYTHROMYCIN treats PERTUSSIS,95,110,,103,122,treats,0.987878339907213,907514-FS1-2,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN,RO-may_treat
503460438,7/16/2014 15:02:09,,1324288888,7/16/2014 15:01:19,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,ERYTHROMYCIN treats PERTUSSIS,95,110,,103,122,treats,0.987878339907213,907514-FS1-2,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN,RO-may_treat
503460438,7/16/2014 15:35:07,,1324300047,7/16/2014 15:34:35,instagc,0.7538,19636746,USA,NY,Andover,192.182.216.225,ERYTHROMYCIN treats PERTUSSIS,95,110,,103,122,treats,0.987878339907213,907514-FS1-2,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN,RO-may_treat
503460438,7/16/2014 17:18:03,,1324343863,7/16/2014 17:17:32,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,ERYTHROMYCIN treats PERTUSSIS,95,110,,103,122,treats,0.987878339907213,907514-FS1-2,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN,RO-may_treat
503460438,7/16/2014 18:22:36,,1324399026,7/16/2014 18:22:20,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,ERYTHROMYCIN treats PERTUSSIS,95,110,,103,122,treats,0.987878339907213,907514-FS1-2,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN,RO-may_treat
503460438,7/16/2014 18:34:12,,1324404150,7/16/2014 18:34:02,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,ERYTHROMYCIN treats PERTUSSIS,95,110,,103,122,treats,0.987878339907213,907514-FS1-2,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of PERTUSSIS: the ERYTHROMYCIN Study Group.,PERTUSSIS,ERYTHROMYCIN,RO-may_treat
503460439,7/16/2014 13:08:23,,1324244725,7/16/2014 13:08:03,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,BRAIN is location of STROKE,84,28,,88,34,is location of,0.963086824686154,902042-FS1-9,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE,RO-disease_has_primary_anatomic_site
503460439,7/16/2014 13:19:58,,1324249312,7/16/2014 13:19:51,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,BRAIN is location of STROKE,84,28,,88,34,is location of,0.963086824686154,902042-FS1-9,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE,RO-disease_has_primary_anatomic_site
503460439,7/16/2014 13:23:49,,1324250779,7/16/2014 13:23:25,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,BRAIN is location of STROKE,84,28,,88,34,is location of,0.963086824686154,902042-FS1-9,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE,RO-disease_has_primary_anatomic_site
503460439,7/16/2014 13:30:58,,1324253975,7/16/2014 13:30:20,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,BRAIN is location of STROKE,84,28,,88,34,is location of,0.963086824686154,902042-FS1-9,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE,RO-disease_has_primary_anatomic_site
503460439,7/16/2014 14:54:22,,1324285798,7/16/2014 14:53:58,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,BRAIN is location of STROKE,84,28,,88,34,is location of,0.963086824686154,902042-FS1-9,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE,RO-disease_has_primary_anatomic_site
503460439,7/16/2014 16:38:36,,1324329833,7/16/2014 16:38:25,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,BRAIN is location of STROKE,84,28,,88,34,is location of,0.963086824686154,902042-FS1-9,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE,RO-disease_has_primary_anatomic_site
503460439,7/16/2014 16:38:56,,1324330049,7/16/2014 16:38:45,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,STROKE is location of BRAIN,84,28,,88,34,is location of,0.963086824686154,902042-FS1-9,In most of the patients the STROKE came as a debut of vascular abnormalities in the BRAIN,BRAIN,STROKE,RO-disease_has_primary_anatomic_site
503460440,7/16/2014 13:16:44,,1324248051,7/16/2014 13:16:10,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,no_relation,47,0,,86,18,causes,0.320256307610174,902397-FS1-4,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460440,7/16/2014 13:33:20,,1324255057,7/16/2014 13:32:41,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,PEMPHIGUS VULGARIS causes DISEASE OF THE SKIN AND MUCOUS MEMBRANES,47,0,,86,18,causes,0.320256307610174,902397-FS1-4,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460440,7/16/2014 14:16:41,,1324272151,7/16/2014 14:16:20,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,no_relation,47,0,,86,18,causes,0.320256307610174,902397-FS1-4,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460440,7/16/2014 14:47:36,,1324283731,7/16/2014 14:46:28,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,no_relation,47,0,,86,18,causes,0.320256307610174,902397-FS1-4,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460440,7/16/2014 15:49:47,,1324306100,7/16/2014 15:49:31,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,47,0,,86,18,causes,0.320256307610174,902397-FS1-4,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460440,7/16/2014 16:40:10,,1324330759,7/16/2014 16:39:49,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,PEMPHIGUS VULGARIS causes DISEASE OF THE SKIN AND MUCOUS MEMBRANES,47,0,,86,18,causes,0.320256307610174,902397-FS1-4,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460440,7/16/2014 17:04:38,,1324339611,7/16/2014 17:04:17,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,PEMPHIGUS VULGARIS causes DISEASE OF THE SKIN AND MUCOUS MEMBRANES,47,0,,86,18,causes,0.320256307610174,902397-FS1-4,PEMPHIGUS VULGARIS is an autoimmune blistering DISEASE OF THE SKIN AND MUCOUS MEMBRANES that is caused by anti desmoglein 3 IgG autoantibodies.,DISEASE OF THE SKIN AND MUCOUS MEMBRANES,PEMPHIGUS VULGARIS,RO-disease_has_primary_anatomic_site
503460441,7/16/2014 14:18:23,,1324272897,7/16/2014 14:17:58,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,no_relation,13,91,,28,119,causes,0.771516749810459,902718-FS1-4,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460441,7/16/2014 14:26:27,,1324276081,7/16/2014 14:26:04,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,CALCIUM DEPOSITS causes EXTRASKELETAL OSTEOCHONDROMA,13,91,,28,119,causes,0.771516749810459,902718-FS1-4,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460441,7/16/2014 16:56:52,,1324336997,7/16/2014 16:56:12,instagc,0.6306,14941596,USA,KY,Erlanger,74.140.124.145,no_relation,13,91,,28,119,causes,0.771516749810459,902718-FS1-4,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460441,7/16/2014 17:05:26,,1324339825,7/16/2014 17:05:00,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,EXTRASKELETAL OSTEOCHONDROMA causes CALCIUM DEPOSITS,13,91,,28,119,causes,0.771516749810459,902718-FS1-4,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460441,7/16/2014 17:17:22,,1324343614,7/16/2014 17:16:22,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,CALCIUM DEPOSITS causes EXTRASKELETAL OSTEOCHONDROMA,13,91,,28,119,causes,0.771516749810459,902718-FS1-4,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460441,7/16/2014 18:00:01,,1324377885,7/16/2014 17:59:27,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,EXTRASKELETAL OSTEOCHONDROMA causes CALCIUM DEPOSITS,13,91,,28,119,causes,0.771516749810459,902718-FS1-4,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460441,7/16/2014 18:34:23,,1324404223,7/16/2014 18:34:13,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,13,91,,28,119,causes,0.771516749810459,902718-FS1-4,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460442,7/16/2014 13:14:21,,1324247121,7/16/2014 13:13:07,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,FISH OIL treats CARDIAC ARRHYTHMIAS,14,78,,32,86,treats,0.975900072948533,907011-FS1-2,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL,RO-may_prevent
503460442,7/16/2014 13:22:21,,1324250286,7/16/2014 13:22:00,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,FISH OIL treats CARDIAC ARRHYTHMIAS,14,78,,32,86,treats,0.975900072948533,907011-FS1-2,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL,RO-may_prevent
503460442,7/16/2014 13:51:54,,1324261769,7/16/2014 13:51:21,instagc,0.7333,13763729,USA,"","",75.182.89.225,FISH OIL treats CARDIAC ARRHYTHMIAS,14,78,,32,86,treats,0.975900072948533,907011-FS1-2,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL,RO-may_prevent
503460442,7/16/2014 14:25:14,,1324275635,7/16/2014 14:24:44,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,FISH OIL treats CARDIAC ARRHYTHMIAS,14,78,,32,86,treats,0.975900072948533,907011-FS1-2,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL,RO-may_prevent
503460442,7/16/2014 15:02:43,,1324289128,7/16/2014 15:02:10,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,FISH OIL treats CARDIAC ARRHYTHMIAS,14,78,,32,86,treats,0.975900072948533,907011-FS1-2,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL,RO-may_prevent
503460442,7/16/2014 15:35:50,,1324300295,7/16/2014 15:35:07,instagc,0.7538,19636746,USA,NY,Andover,192.182.216.225,no_relation,14,78,,32,86,treats,0.975900072948533,907011-FS1-2,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL,RO-may_prevent
503460442,7/16/2014 15:37:07,,1324300775,7/16/2014 15:36:48,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,no_relation,14,78,,32,86,treats,0.975900072948533,907011-FS1-2,Prevention of CARDIAC ARRHYTHMIAS and sudden death is demonstrable at fish or FISH OIL intakes that have little or no effect on blood pressure or plasma lipids.,CARDIAC ARRHYTHMIAS,FISH OIL,RO-may_prevent
503460443,7/16/2014 13:07:57,,1324244522,7/16/2014 13:07:36,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,ENDOTOXIN causes ENDOTOXIC SHOCK,201,141,,209,156,causes,0.956182887467515,903981-FS1-4,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK,RO-has_causative_agent
503460443,7/16/2014 13:09:08,,1324244974,7/16/2014 13:08:40,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,ENDOTOXIC SHOCK causes ENDOTOXIN,201,141,,209,156,causes,0.956182887467515,903981-FS1-4,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK,RO-has_causative_agent
503460443,7/16/2014 13:15:33,,1324247600,7/16/2014 13:15:02,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,ENDOTOXIC SHOCK causes ENDOTOXIN,201,141,,209,156,causes,0.956182887467515,903981-FS1-4,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK,RO-has_causative_agent
503460443,7/16/2014 13:26:17,,1324251881,7/16/2014 13:25:35,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,ENDOTOXIN causes ENDOTOXIC SHOCK,201,141,,209,156,causes,0.956182887467515,903981-FS1-4,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK,RO-has_causative_agent
503460443,7/16/2014 13:33:56,,1324255331,7/16/2014 13:33:15,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,no_relation,201,141,,209,156,causes,0.956182887467515,903981-FS1-4,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK,RO-has_causative_agent
503460443,7/16/2014 14:26:55,,1324276221,7/16/2014 14:26:29,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,ENDOTOXIN causes ENDOTOXIC SHOCK,201,141,,209,156,causes,0.956182887467515,903981-FS1-4,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK,RO-has_causative_agent
503460443,7/16/2014 15:34:16,,1324299721,7/16/2014 15:33:48,instagc,0.7538,19636746,USA,NY,Andover,192.182.216.225,ENDOTOXIN causes ENDOTOXIC SHOCK,201,141,,209,156,causes,0.956182887467515,903981-FS1-4,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of ENDOTOXIC SHOCK was established by intravenous injection of ENDOTOXIN into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",ENDOTOXIN,ENDOTOXIC SHOCK,RO-has_causative_agent
503460444,7/16/2014 13:06:16,,1324243827,7/16/2014 13:05:51,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,SKIN is location of INFLAMMATORY DERMATOSES,156,100,,159,123,is location of,0.975900072948533,902112-FS1-9,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES,RO-disease_has_primary_anatomic_site
503460444,7/16/2014 13:08:20,,1324244701,7/16/2014 13:07:58,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,SKIN is location of INFLAMMATORY DERMATOSES,156,100,,159,123,is location of,0.975900072948533,902112-FS1-9,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES,RO-disease_has_primary_anatomic_site
503460444,7/16/2014 13:16:14,,1324247802,7/16/2014 13:15:51,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,SKIN is location of INFLAMMATORY DERMATOSES,156,100,,159,123,is location of,0.975900072948533,902112-FS1-9,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES,RO-disease_has_primary_anatomic_site
503460444,7/16/2014 13:26:46,,1324252122,7/16/2014 13:26:18,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,SKIN is location of INFLAMMATORY DERMATOSES,156,100,,159,123,is location of,0.975900072948533,902112-FS1-9,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES,RO-disease_has_primary_anatomic_site
503460444,7/16/2014 13:52:17,,1324261889,7/16/2014 13:51:55,instagc,0.7333,13763729,USA,"","",75.182.89.225,SKIN is location of INFLAMMATORY DERMATOSES,156,100,,159,123,is location of,0.975900072948533,902112-FS1-9,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES,RO-disease_has_primary_anatomic_site
503460444,7/16/2014 14:17:26,,1324272496,7/16/2014 14:17:06,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,SKIN is location of INFLAMMATORY DERMATOSES,156,100,,159,123,is location of,0.975900072948533,902112-FS1-9,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES,RO-disease_has_primary_anatomic_site
503460444,7/16/2014 14:53:37,,1324285583,7/16/2014 14:53:00,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,no_relation,156,100,,159,123,is location of,0.975900072948533,902112-FS1-9,The distribution of OKM 5 positive dendritic cells in the epidermis was investigated in 75 cases of INFLAMMATORY DERMATOSES and in 14 cases of normal human SKIN by immunohistochemical and morphometric methods.,SKIN,INFLAMMATORY DERMATOSES,RO-disease_has_primary_anatomic_site
503460445,7/16/2014 13:05:50,,1324243666,7/16/2014 13:05:25,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,no_relation,136,107,,152,127,contraindicates,0.38490017945975,900444-FS1-10,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP,RO-cause_of
503460445,7/16/2014 13:16:08,,1324247777,7/16/2014 13:15:45,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,no_relation,136,107,,152,127,contraindicates,0.38490017945975,900444-FS1-10,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP,RO-cause_of
503460445,7/16/2014 13:16:21,,1324247840,7/16/2014 13:16:14,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,NICKEL ALLERGY GROUP contraindicates NON ALLERGY GROUP,136,107,,152,127,contraindicates,0.38490017945975,900444-FS1-10,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP,RO-cause_of
503460445,7/16/2014 13:18:13,,1324248630,7/16/2014 13:17:32,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,NON ALLERGY GROUP contraindicates NICKEL ALLERGY GROUP,136,107,,152,127,contraindicates,0.38490017945975,900444-FS1-10,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP,RO-cause_of
503460445,7/16/2014 15:01:18,,1324288449,7/16/2014 15:00:44,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,no_relation,136,107,,152,127,contraindicates,0.38490017945975,900444-FS1-10,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP,RO-cause_of
503460445,7/16/2014 15:44:18,,1324303809,7/16/2014 15:44:02,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,no_relation,136,107,,152,127,contraindicates,0.38490017945975,900444-FS1-10,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP,RO-cause_of
503460445,7/16/2014 17:04:58,,1324339726,7/16/2014 17:04:54,prodege,0.4233,12944140,GBR,C8,Croydon,92.21.8.174,NICKEL ALLERGY GROUP contraindicates NON ALLERGY GROUP,136,107,,152,127,contraindicates,0.38490017945975,900444-FS1-10,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the NICKEL ALLERGY GROUP and the NON ALLERGY GROUP.,NON ALLERGY GROUP,NICKEL ALLERGY GROUP,RO-cause_of
503460446,7/16/2014 13:06:26,,1324243909,7/16/2014 13:06:05,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,123,26,,143,50,treats,1,908308-FS1-2,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT,RO-may_treat
503460446,7/16/2014 13:20:03,,1324249364,7/16/2014 13:19:57,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,DELUSIONAL DEPRESSION treats TRICYCLIC ANTIDEPRESSANT,123,26,,143,50,treats,1,908308-FS1-2,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT,RO-may_treat
503460446,7/16/2014 14:27:33,,1324276507,7/16/2014 14:26:42,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,123,26,,143,50,treats,1,908308-FS1-2,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT,RO-may_treat
503460446,7/16/2014 14:46:27,,1324283367,7/16/2014 14:45:59,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,123,26,,143,50,treats,1,908308-FS1-2,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT,RO-may_treat
503460446,7/16/2014 15:35:07,,1324300048,7/16/2014 15:34:35,instagc,0.7538,19636746,USA,NY,Andover,192.182.216.225,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,123,26,,143,50,treats,1,908308-FS1-2,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT,RO-may_treat
503460446,7/16/2014 15:36:15,,1324300452,7/16/2014 15:36:09,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,TRICYCLIC ANTIDEPRESSANT treats DELUSIONAL DEPRESSION,123,26,,143,50,treats,1,908308-FS1-2,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT,RO-may_treat
503460446,7/16/2014 16:38:36,,1324329841,7/16/2014 16:38:25,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,DELUSIONAL DEPRESSION treats TRICYCLIC ANTIDEPRESSANT,123,26,,143,50,treats,1,908308-FS1-2,"Since the introduction of TRICYCLIC ANTIDEPRESSANT for the treatment of depressive patients, it has been discussed whether DELUSIONAL DEPRESSION should be designated as a distinct syndrome or merely a severe variant of major depression.",DELUSIONAL DEPRESSION,TRICYCLIC ANTIDEPRESSANT,RO-may_treat
503460447,7/16/2014 13:13:25,,1324246718,7/16/2014 13:13:05,instagc,0.7083,18960682,GBR,"","",86.29.147.112,MALIGNANT HYPERTHERMIA diagnosed by HALOTHANE,0,54,,21,63,diagnosed by,0.993127066322841,906665-FS1-13,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE,RO-may_diagnose
503460447,7/16/2014 13:18:55,,1324248917,7/16/2014 13:18:30,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,MALIGNANT HYPERTHERMIA diagnosed by HALOTHANE,0,54,,21,63,diagnosed by,0.993127066322841,906665-FS1-13,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE,RO-may_diagnose
503460447,7/16/2014 13:19:24,,1324249068,7/16/2014 13:19:15,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,MALIGNANT HYPERTHERMIA diagnosed by HALOTHANE,0,54,,21,63,diagnosed by,0.993127066322841,906665-FS1-13,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE,RO-may_diagnose
503460447,7/16/2014 14:45:33,,1324283121,7/16/2014 14:44:56,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,MALIGNANT HYPERTHERMIA diagnosed by HALOTHANE,0,54,,21,63,diagnosed by,0.993127066322841,906665-FS1-13,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE,RO-may_diagnose
503460447,7/16/2014 15:13:27,,1324293085,7/16/2014 15:12:46,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,MALIGNANT HYPERTHERMIA diagnosed by HALOTHANE,0,54,,21,63,diagnosed by,0.993127066322841,906665-FS1-13,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE,RO-may_diagnose
503460447,7/16/2014 15:41:47,,1324302761,7/16/2014 15:41:25,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,no_relation,0,54,,21,63,diagnosed by,0.993127066322841,906665-FS1-13,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE,RO-may_diagnose
503460447,7/16/2014 16:37:24,,1324329005,7/16/2014 16:37:07,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,MALIGNANT HYPERTHERMIA diagnosed by HALOTHANE,0,54,,21,63,diagnosed by,0.993127066322841,906665-FS1-13,MALIGNANT HYPERTHERMIA susceptibility was assessed by HALOTHANE challenge of pigs.,MALIGNANT HYPERTHERMIA,HALOTHANE,RO-may_diagnose
503460448,7/16/2014 13:14:01,,1324246990,7/16/2014 13:13:38,instagc,0.7083,18960682,GBR,"","",86.29.147.112,no_relation,159,196,,174,230,diagnosed by,0.753778361444409,901897-FS1-13,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460448,7/16/2014 13:19:25,,1324249074,7/16/2014 13:18:57,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosed by HEMOPHAGOCYTOSIS,159,196,,174,230,diagnosed by,0.753778361444409,901897-FS1-13,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460448,7/16/2014 13:21:59,,1324250135,7/16/2014 13:21:24,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosed by HEMOPHAGOCYTOSIS,159,196,,174,230,diagnosed by,0.753778361444409,901897-FS1-13,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460448,7/16/2014 13:32:50,,1324254799,7/16/2014 13:32:18,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosed by HEMOPHAGOCYTOSIS,159,196,,174,230,diagnosed by,0.753778361444409,901897-FS1-13,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460448,7/16/2014 14:29:07,,1324277212,7/16/2014 14:28:28,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosed by HEMOPHAGOCYTOSIS,159,196,,174,230,diagnosed by,0.753778361444409,901897-FS1-13,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460448,7/16/2014 14:30:50,,1324278047,7/16/2014 14:30:32,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosed by HEMOPHAGOCYTOSIS,159,196,,174,230,diagnosed by,0.753778361444409,901897-FS1-13,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460448,7/16/2014 14:45:33,,1324283118,7/16/2014 14:44:56,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS diagnosed by HEMOPHAGOCYTOSIS,159,196,,174,230,diagnosed by,0.753778361444409,901897-FS1-13,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460449,7/16/2014 13:07:55,,1324244518,7/16/2014 13:07:33,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,GRAVES' DISEASE causes GRAVES' THYROTOXICOSIS,115,149,,129,171,causes,0.737209780774486,900460-FS1-4,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS,RO-cause_of
503460449,7/16/2014 13:09:46,,1324245240,7/16/2014 13:09:10,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,GRAVES' DISEASE causes GRAVES' THYROTOXICOSIS,115,149,,129,171,causes,0.737209780774486,900460-FS1-4,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS,RO-cause_of
503460449,7/16/2014 13:14:46,,1324247316,7/16/2014 13:14:31,instagc,0.7083,18960682,GBR,"","",86.29.147.112,no_relation,115,149,,129,171,causes,0.737209780774486,900460-FS1-4,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS,RO-cause_of
503460449,7/16/2014 13:23:29,,1324250627,7/16/2014 13:22:43,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,GRAVES' DISEASE causes GRAVES' THYROTOXICOSIS,115,149,,129,171,causes,0.737209780774486,900460-FS1-4,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS,RO-cause_of
503460449,7/16/2014 13:28:16,,1324252756,7/16/2014 13:27:29,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,GRAVES' THYROTOXICOSIS causes GRAVES' DISEASE,115,149,,129,171,causes,0.737209780774486,900460-FS1-4,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS,RO-cause_of
503460449,7/16/2014 15:43:17,,1324303301,7/16/2014 15:42:59,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,GRAVES' DISEASE causes GRAVES' THYROTOXICOSIS,115,149,,129,171,causes,0.737209780774486,900460-FS1-4,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS,RO-cause_of
503460449,7/16/2014 17:06:12,,1324339966,7/16/2014 17:06:05,prodege,0.4233,12944140,GBR,C8,Croydon,92.21.8.174,GRAVES' THYROTOXICOSIS causes GRAVES' DISEASE,115,149,,129,171,causes,0.737209780774486,900460-FS1-4,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with GRAVES' DISEASE who relapsed into GRAVES' THYROTOXICOSIS",GRAVES' DISEASE,GRAVES' THYROTOXICOSIS,RO-cause_of
503460450,7/16/2014 13:15:01,,1324247412,7/16/2014 13:14:37,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CANCER,101,152,,123,170,causes,0.676123403782813,902927-FS1-4,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,RO-disease_may_have_finding
503460450,7/16/2014 13:31:29,,1324254203,7/16/2014 13:30:49,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,POSTMENOPAUSAL BLEEDING causes ENDOMETRIAL CANCER,101,152,,123,170,causes,0.676123403782813,902927-FS1-4,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,RO-disease_may_have_finding
503460450,7/16/2014 13:34:53,,1324255751,7/16/2014 13:34:21,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,101,152,,123,170,causes,0.676123403782813,902927-FS1-4,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,RO-disease_may_have_finding
503460450,7/16/2014 14:30:12,,1324277717,7/16/2014 14:29:34,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,no_relation,101,152,,123,170,causes,0.676123403782813,902927-FS1-4,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,RO-disease_may_have_finding
503460450,7/16/2014 14:31:44,,1324278356,7/16/2014 14:30:51,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,101,152,,123,170,causes,0.676123403782813,902927-FS1-4,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,RO-disease_may_have_finding
503460450,7/16/2014 15:09:41,,1324291858,7/16/2014 15:09:35,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,101,152,,123,170,causes,0.676123403782813,902927-FS1-4,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,RO-disease_may_have_finding
503460450,7/16/2014 16:39:25,,1324330321,7/16/2014 16:39:02,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,ENDOMETRIAL CANCER causes POSTMENOPAUSAL BLEEDING,101,152,,123,170,causes,0.676123403782813,902927-FS1-4,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without POSTMENOPAUSAL BLEEDING are at low risk for having ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,RO-disease_may_have_finding
503460451,7/16/2014 13:27:26,,1324252442,7/16/2014 13:26:48,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,MONTELUKAST treats ASTHMA,53,135,,58,146,treats,0.953998092005724,907799-FS1-2,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST,RO-may_treat
503460451,7/16/2014 14:25:37,,1324275797,7/16/2014 14:25:16,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,MONTELUKAST treats ASTHMA,53,135,,58,146,treats,0.953998092005724,907799-FS1-2,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST,RO-may_treat
503460451,7/16/2014 15:14:24,,1324293440,7/16/2014 15:13:29,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,ASTHMA treats MONTELUKAST,53,135,,58,146,treats,0.953998092005724,907799-FS1-2,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST,RO-may_treat
503460451,7/16/2014 15:48:57,,1324305765,7/16/2014 15:48:35,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,MONTELUKAST treats ASTHMA,53,135,,58,146,treats,0.953998092005724,907799-FS1-2,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST,RO-may_treat
503460451,7/16/2014 17:19:28,,1324344230,7/16/2014 17:18:47,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,MONTELUKAST treats ASTHMA,53,135,,58,146,treats,0.953998092005724,907799-FS1-2,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST,RO-may_treat
503460451,7/16/2014 17:27:09,,1324347279,7/16/2014 17:26:49,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,MONTELUKAST treats ASTHMA,53,135,,58,146,treats,0.953998092005724,907799-FS1-2,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST,RO-may_treat
503460451,7/16/2014 17:44:40,,1324361623,7/16/2014 17:44:09,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,MONTELUKAST treats ASTHMA,53,135,,58,146,treats,0.953998092005724,907799-FS1-2,Because montelukast is efficacious for patients with ASTHMA selected patients with mild asthma and rhinitis may be good candidates for MONTELUKAST.,ASTHMA,MONTELUKAST,RO-may_treat
503460452,7/16/2014 13:08:23,,1324244728,7/16/2014 13:08:03,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,KNEE JOINTS is location of CLINICAL ARTHRITIS,109,150,,119,168,is location of,0.975900072948533,902085-FS1-9,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS,RO-disease_has_primary_anatomic_site
503460452,7/16/2014 13:26:02,,1324251758,7/16/2014 13:25:31,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,KNEE JOINTS is location of CLINICAL ARTHRITIS,109,150,,119,168,is location of,0.975900072948533,902085-FS1-9,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS,RO-disease_has_primary_anatomic_site
503460452,7/16/2014 14:30:30,,1324277854,7/16/2014 14:29:50,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,KNEE JOINTS is location of CLINICAL ARTHRITIS,109,150,,119,168,is location of,0.975900072948533,902085-FS1-9,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS,RO-disease_has_primary_anatomic_site
503460452,7/16/2014 17:28:40,,1324348329,7/16/2014 17:28:14,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,KNEE JOINTS is location of CLINICAL ARTHRITIS,109,150,,119,168,is location of,0.975900072948533,902085-FS1-9,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS,RO-disease_has_primary_anatomic_site
503460452,7/16/2014 18:22:36,,1324399029,7/16/2014 18:22:20,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,KNEE JOINTS is location of CLINICAL ARTHRITIS,109,150,,119,168,is location of,0.975900072948533,902085-FS1-9,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS,RO-disease_has_primary_anatomic_site
503460452,7/16/2014 18:34:12,,1324404149,7/16/2014 18:34:02,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,KNEE JOINTS is location of CLINICAL ARTHRITIS,109,150,,119,168,is location of,0.975900072948533,902085-FS1-9,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS,RO-disease_has_primary_anatomic_site
503460452,7/16/2014 18:46:43,,1324410564,7/16/2014 18:45:58,eup_slw,0.5873,28186528,USA,IN,Bloomington,74.204.124.9,KNEE JOINTS is location of CLINICAL ARTHRITIS,109,150,,119,168,is location of,0.975900072948533,902085-FS1-9,"Shortly after intravenous injection of 99mTechnetium pertechnetate (99mTcO4 )(200 muCi), the activity of the KNEE JOINTS was studied in patients with CLINICAL ARTHRITIS of one or both knees and compared with that in normal subjects.",KNEE JOINTS,CLINICAL ARTHRITIS,RO-disease_has_primary_anatomic_site
503460453,7/16/2014 13:33:23,,1324255067,7/16/2014 13:32:52,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,FLUORIDE treats CARIES,243,188,,248,196,treats,0.976187060183953,907105-FS1-2,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE,RO-may_prevent
503460453,7/16/2014 15:43:52,,1324303639,7/16/2014 15:43:37,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,no_relation,243,188,,248,196,treats,0.976187060183953,907105-FS1-2,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE,RO-may_prevent
503460453,7/16/2014 15:50:03,,1324306232,7/16/2014 15:49:49,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,243,188,,248,196,treats,0.976187060183953,907105-FS1-2,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE,RO-may_prevent
503460453,7/16/2014 16:54:23,,1324336123,7/16/2014 16:53:34,clixsense,0.4786,6497991,USA,NC,Clinton,204.211.52.144,FLUORIDE treats CARIES,243,188,,248,196,treats,0.976187060183953,907105-FS1-2,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE,RO-may_prevent
503460453,7/16/2014 16:56:11,,1324336773,7/16/2014 16:55:13,instagc,0.6306,14941596,USA,KY,Erlanger,74.140.124.145,FLUORIDE treats CARIES,243,188,,248,196,treats,0.976187060183953,907105-FS1-2,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE,RO-may_prevent
503460453,7/16/2014 18:34:02,,1324404051,7/16/2014 18:33:49,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,243,188,,248,196,treats,0.976187060183953,907105-FS1-2,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE,RO-may_prevent
503460453,7/16/2014 18:46:43,,1324410565,7/16/2014 18:45:58,eup_slw,0.5873,28186528,USA,IN,Bloomington,74.204.124.9,no_relation,243,188,,248,196,treats,0.976187060183953,907105-FS1-2,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical FLUORIDE treatments (such as gels and rinses) or other CARIES management methods.",CARIES,FLUORIDE,RO-may_prevent
503460454,7/16/2014 13:08:02,,1324244549,7/16/2014 13:07:30,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,MYASTHENIA GRAVIS diagnosed by NEOSTIGMINE,0,46,,16,57,diagnosed by,0.997054485501582,906866-FS1-13,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
503460454,7/16/2014 13:24:52,,1324251253,7/16/2014 13:24:24,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,MYASTHENIA GRAVIS diagnosed by NEOSTIGMINE,0,46,,16,57,diagnosed by,0.997054485501582,906866-FS1-13,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
503460454,7/16/2014 14:30:12,,1324277684,7/16/2014 14:29:34,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,MYASTHENIA GRAVIS diagnosed by NEOSTIGMINE,0,46,,16,57,diagnosed by,0.997054485501582,906866-FS1-13,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
503460454,7/16/2014 15:00:10,,1324288005,7/16/2014 14:59:13,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,MYASTHENIA GRAVIS diagnosed by NEOSTIGMINE,0,46,,16,57,diagnosed by,0.997054485501582,906866-FS1-13,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
503460454,7/16/2014 15:36:18,,1324300477,7/16/2014 15:35:51,instagc,0.7538,19636746,USA,NY,Andover,192.182.216.225,MYASTHENIA GRAVIS diagnosed by NEOSTIGMINE,0,46,,16,57,diagnosed by,0.997054485501582,906866-FS1-13,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
503460454,7/16/2014 16:56:52,,1324336999,7/16/2014 16:56:12,instagc,0.6306,14941596,USA,KY,Erlanger,74.140.124.145,MYASTHENIA GRAVIS diagnosed by NEOSTIGMINE,0,46,,16,57,diagnosed by,0.997054485501582,906866-FS1-13,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
503460454,7/16/2014 17:05:26,,1324339837,7/16/2014 17:05:00,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,MYASTHENIA GRAVIS diagnosed by NEOSTIGMINE,0,46,,16,57,diagnosed by,0.997054485501582,906866-FS1-13,MYASTHENIA GRAVIS was confirmed by a positive NEOSTIGMINE test.,MYASTHENIA GRAVIS,NEOSTIGMINE,RO-may_diagnose
503460455,7/16/2014 13:11:19,,1324245868,7/16/2014 13:11:09,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,HEPARIN treats MYOCARDIAL INFARCTION,70,172,,90,179,treats,0.949425326555083,908250-FS1-2,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN,RO-may_treat
503460455,7/16/2014 13:14:16,,1324247062,7/16/2014 13:14:02,instagc,0.7083,18960682,GBR,"","",86.29.147.112,HEPARIN treats MYOCARDIAL INFARCTION,70,172,,90,179,treats,0.949425326555083,908250-FS1-2,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN,RO-may_treat
503460455,7/16/2014 13:19:58,,1324249311,7/16/2014 13:19:51,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,HEPARIN treats MYOCARDIAL INFARCTION,70,172,,90,179,treats,0.949425326555083,908250-FS1-2,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN,RO-may_treat
503460455,7/16/2014 13:25:30,,1324251561,7/16/2014 13:25:00,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,HEPARIN treats MYOCARDIAL INFARCTION,70,172,,90,179,treats,0.949425326555083,908250-FS1-2,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN,RO-may_treat
503460455,7/16/2014 13:35:30,,1324256006,7/16/2014 13:34:54,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,HEPARIN treats MYOCARDIAL INFARCTION,70,172,,90,179,treats,0.949425326555083,908250-FS1-2,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN,RO-may_treat
503460455,7/16/2014 13:50:13,,1324261170,7/16/2014 13:49:35,instagc,0.7333,13763729,USA,"","",75.182.89.225,HEPARIN treats MYOCARDIAL INFARCTION,70,172,,90,179,treats,0.949425326555083,908250-FS1-2,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN,RO-may_treat
503460455,7/16/2014 17:04:16,,1324339465,7/16/2014 17:03:58,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,HEPARIN treats MYOCARDIAL INFARCTION,70,172,,90,179,treats,0.949425326555083,908250-FS1-2,A meta analysis of these two studies showed that the risk of death or MYOCARDIAL INFARCTION was consistently approximately 20% lower in enoxaparin treated patients than in HEPARIN treated patients.,MYOCARDIAL INFARCTION,HEPARIN,RO-may_treat
503460456,7/16/2014 13:09:46,,1324245239,7/16/2014 13:09:10,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,PODOPHYLLOTOXIN treats PENILE WARTS,151,104,,162,119,treats,0.995893206467704,907713-FS1-2,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN,RO-may_treat
503460456,7/16/2014 13:11:05,,1324245750,7/16/2014 13:10:52,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,no_relation,151,104,,162,119,treats,0.995893206467704,907713-FS1-2,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN,RO-may_treat
503460456,7/16/2014 13:14:16,,1324247066,7/16/2014 13:14:02,instagc,0.7083,18960682,GBR,"","",86.29.147.112,PODOPHYLLOTOXIN treats PENILE WARTS,151,104,,162,119,treats,0.995893206467704,907713-FS1-2,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN,RO-may_treat
503460456,7/16/2014 14:27:21,,1324276389,7/16/2014 14:26:57,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,PODOPHYLLOTOXIN treats PENILE WARTS,151,104,,162,119,treats,0.995893206467704,907713-FS1-2,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN,RO-may_treat
503460456,7/16/2014 14:31:44,,1324278355,7/16/2014 14:30:51,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,PENILE WARTS treats PODOPHYLLOTOXIN,151,104,,162,119,treats,0.995893206467704,907713-FS1-2,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN,RO-may_treat
503460456,7/16/2014 15:44:01,,1324303691,7/16/2014 15:43:53,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,PODOPHYLLOTOXIN treats PENILE WARTS,151,104,,162,119,treats,0.995893206467704,907713-FS1-2,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN,RO-may_treat
503460456,7/16/2014 16:39:01,,1324330120,7/16/2014 16:38:39,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,PODOPHYLLOTOXIN treats PENILE WARTS,151,104,,162,119,treats,0.995893206467704,907713-FS1-2,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v PODOPHYLLOTOXIN 0.5% for the self treatment of PENILE WARTS: a double blind randomised study.",PENILE WARTS,PODOPHYLLOTOXIN,RO-may_treat
503460457,7/16/2014 13:06:16,,1324243826,7/16/2014 13:05:51,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,BORDETELLA PERTUSSIS causes WHOOPING COUGH,47,91,,66,105,causes,1,903889-FS1-4,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH,RO-has_causative_agent
503460457,7/16/2014 13:12:03,,1324246133,7/16/2014 13:11:53,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,BORDETELLA PERTUSSIS causes WHOOPING COUGH,47,91,,66,105,causes,1,903889-FS1-4,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH,RO-has_causative_agent
503460457,7/16/2014 13:13:37,,1324246825,7/16/2014 13:13:26,instagc,0.7083,18960682,GBR,"","",86.29.147.112,BORDETELLA PERTUSSIS causes WHOOPING COUGH,47,91,,66,105,causes,1,903889-FS1-4,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH,RO-has_causative_agent
503460457,7/16/2014 13:17:32,,1324248344,7/16/2014 13:16:42,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,BORDETELLA PERTUSSIS causes WHOOPING COUGH,47,91,,66,105,causes,1,903889-FS1-4,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH,RO-has_causative_agent
503460457,7/16/2014 13:21:38,,1324249990,7/16/2014 13:21:26,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,BORDETELLA PERTUSSIS causes WHOOPING COUGH,47,91,,66,105,causes,1,903889-FS1-4,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH,RO-has_causative_agent
503460457,7/16/2014 13:33:55,,1324255328,7/16/2014 13:33:25,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,BORDETELLA PERTUSSIS causes WHOOPING COUGH,47,91,,66,105,causes,1,903889-FS1-4,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH,RO-has_causative_agent
503460457,7/16/2014 14:29:33,,1324277423,7/16/2014 14:29:08,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,BORDETELLA PERTUSSIS causes WHOOPING COUGH,47,91,,66,105,causes,1,903889-FS1-4,Pertussis toxin is a major virulence factor of BORDETELLA PERTUSSIS the causative agent of WHOOPING COUGH,BORDETELLA PERTUSSIS,WHOOPING COUGH,RO-has_causative_agent
503460458,7/16/2014 13:19:34,,1324249147,7/16/2014 13:19:24,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,PARACETAMOL treats MINOR PAIN,74,0,,83,11,treats,0.936329177569044,908294-FS1-2,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL,RO-may_treat
503460458,7/16/2014 15:00:43,,1324288219,7/16/2014 15:00:11,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,PARACETAMOL treats MINOR PAIN,74,0,,83,11,treats,0.936329177569044,908294-FS1-2,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL,RO-may_treat
503460458,7/16/2014 15:09:33,,1324291826,7/16/2014 15:09:22,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,PARACETAMOL treats MINOR PAIN,74,0,,83,11,treats,0.936329177569044,908294-FS1-2,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL,RO-may_treat
503460458,7/16/2014 15:34:34,,1324299856,7/16/2014 15:34:18,instagc,0.7538,19636746,USA,NY,Andover,192.182.216.225,PARACETAMOL treats MINOR PAIN,74,0,,83,11,treats,0.936329177569044,908294-FS1-2,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL,RO-may_treat
503460458,7/16/2014 17:17:09,,1324343590,7/16/2014 17:16:52,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,PARACETAMOL treats MINOR PAIN,74,0,,83,11,treats,0.936329177569044,908294-FS1-2,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL,RO-may_treat
503460458,7/16/2014 17:17:43,,1324343757,7/16/2014 17:17:24,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,PARACETAMOL treats MINOR PAIN,74,0,,83,11,treats,0.936329177569044,908294-FS1-2,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL,RO-may_treat
503460458,7/16/2014 17:45:09,,1324362101,7/16/2014 17:44:41,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,PARACETAMOL treats MINOR PAIN,74,0,,83,11,treats,0.936329177569044,908294-FS1-2,PARACETAMOL (acetaminophen) was the most common alternative analgesic for MINOR PAIN,MINOR PAIN,PARACETAMOL,RO-may_treat
503460459,7/16/2014 13:06:44,,1324244034,7/16/2014 13:06:25,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,HYPERTENSION diagnosed by BLOOD PRESSURE ELEVATION,92,76,,115,88,diagnosed by,0.35921060405355,904546-FS1-13,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION,RO-has_definitional_manifestation
503460459,7/16/2014 13:14:21,,1324247122,7/16/2014 13:13:07,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,no_relation,92,76,,115,88,diagnosed by,0.35921060405355,904546-FS1-13,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION,RO-has_definitional_manifestation
503460459,7/16/2014 13:19:14,,1324249009,7/16/2014 13:19:06,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,HYPERTENSION diagnosed by BLOOD PRESSURE ELEVATION,92,76,,115,88,diagnosed by,0.35921060405355,904546-FS1-13,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION,RO-has_definitional_manifestation
503460459,7/16/2014 13:23:23,,1324250609,7/16/2014 13:23:03,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,BLOOD PRESSURE ELEVATION diagnosed by HYPERTENSION,92,76,,115,88,diagnosed by,0.35921060405355,904546-FS1-13,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION,RO-has_definitional_manifestation
503460459,7/16/2014 13:24:52,,1324251246,7/16/2014 13:24:24,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,BLOOD PRESSURE ELEVATION diagnosed by HYPERTENSION,92,76,,115,88,diagnosed by,0.35921060405355,904546-FS1-13,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION,RO-has_definitional_manifestation
503460459,7/16/2014 13:29:03,,1324253082,7/16/2014 13:28:22,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,no_relation,92,76,,115,88,diagnosed by,0.35921060405355,904546-FS1-13,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION,RO-has_definitional_manifestation
503460459,7/16/2014 14:27:33,,1324276508,7/16/2014 14:26:42,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,no_relation,92,76,,115,88,diagnosed by,0.35921060405355,904546-FS1-13,The objective of the present study was to assess the impact of a history of HYPERTENSION or BLOOD PRESSURE ELEVATION on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,BLOOD PRESSURE ELEVATION,HYPERTENSION,RO-has_definitional_manifestation
503460460,7/16/2014 13:08:30,,1324244754,7/16/2014 13:07:55,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,CHRONIC LYMPHOCYTIC LEUKEMIA diagnosed by BILATERAL GROIN ADENOPATHY,19,94,,44,122,diagnosed by,0.784464540552736,902567-FS1-13,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,RO-disease_may_have_finding
503460460,7/16/2014 17:08:42,,1324340955,7/16/2014 17:07:52,clixsense,0.5952,19638651,USA,"","",173.23.121.63,no_relation,19,94,,44,122,diagnosed by,0.784464540552736,902567-FS1-13,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,RO-disease_may_have_finding
503460460,7/16/2014 17:28:13,,1324348015,7/16/2014 17:27:09,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,CHRONIC LYMPHOCYTIC LEUKEMIA diagnosed by BILATERAL GROIN ADENOPATHY,19,94,,44,122,diagnosed by,0.784464540552736,902567-FS1-13,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,RO-disease_may_have_finding
503460460,7/16/2014 17:45:38,,1324362707,7/16/2014 17:45:10,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,CHRONIC LYMPHOCYTIC LEUKEMIA diagnosed by BILATERAL GROIN ADENOPATHY,19,94,,44,122,diagnosed by,0.784464540552736,902567-FS1-13,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,RO-disease_may_have_finding
503460460,7/16/2014 18:23:43,,1324399458,7/16/2014 18:23:21,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,CHRONIC LYMPHOCYTIC LEUKEMIA diagnosed by BILATERAL GROIN ADENOPATHY,19,94,,44,122,diagnosed by,0.784464540552736,902567-FS1-13,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,RO-disease_may_have_finding
503460460,7/16/2014 18:34:30,,1324404279,7/16/2014 18:34:24,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,19,94,,44,122,diagnosed by,0.784464540552736,902567-FS1-13,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,RO-disease_may_have_finding
503460460,7/16/2014 18:48:19,,1324411507,7/16/2014 18:47:19,eup_slw,0.5873,28186528,USA,IN,Bloomington,74.204.124.9,CHRONIC LYMPHOCYTIC LEUKEMIA diagnosed by BILATERAL GROIN ADENOPATHY,19,94,,44,122,diagnosed by,0.784464540552736,902567-FS1-13,"Five months later, BILATERAL GROIN ADENOPATHY was biopsy proven to be metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA and the patient died 8 months after the radical vulvectomy.",BILATERAL GROIN ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,RO-disease_may_have_finding
503460461,7/16/2014 13:05:50,,1324243667,7/16/2014 13:05:25,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,28,104,,57,117,causes,0.680413817439772,902782-FS1-4,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA,RO-disease_may_have_finding
503460461,7/16/2014 13:07:33,,1324244318,7/16/2014 13:07:15,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,28,104,,57,117,causes,0.680413817439772,902782-FS1-4,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA,RO-disease_may_have_finding
503460461,7/16/2014 13:21:23,,1324249872,7/16/2014 13:20:53,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,no_relation,28,104,,57,117,causes,0.680413817439772,902782-FS1-4,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA,RO-disease_may_have_finding
503460461,7/16/2014 14:22:21,,1324274529,7/16/2014 14:21:48,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,28,104,,57,117,causes,0.680413817439772,902782-FS1-4,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA,RO-disease_may_have_finding
503460461,7/16/2014 14:33:07,,1324278833,7/16/2014 14:32:44,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,SPONTANEOUS ADRENAL HEMORRHAGE causes NEUROBLASTOMA,28,104,,57,117,causes,0.680413817439772,902782-FS1-4,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA,RO-disease_may_have_finding
503460461,7/16/2014 15:48:57,,1324305764,7/16/2014 15:48:35,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,NEUROBLASTOMA causes SPONTANEOUS ADRENAL HEMORRHAGE,28,104,,57,117,causes,0.680413817439772,902782-FS1-4,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA,RO-disease_may_have_finding
503460461,7/16/2014 16:37:59,,1324329371,7/16/2014 16:37:26,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,NEUROBLASTOMA causes SPONTANEOUS ADRENAL HEMORRHAGE,28,104,,57,117,causes,0.680413817439772,902782-FS1-4,"Less commonly, in newborns, SPONTANEOUS ADRENAL HEMORRHAGE may produce large adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.",SPONTANEOUS ADRENAL HEMORRHAGE,NEUROBLASTOMA,RO-disease_may_have_finding
503460462,7/16/2014 13:07:55,,1324244521,7/16/2014 13:07:33,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,CLOZAPINE treats SCHIZOPHRENIA,128,44,,140,53,treats,1,908255-FS1-2,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE,RO-may_treat
503460462,7/16/2014 13:19:49,,1324249245,7/16/2014 13:19:43,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,SCHIZOPHRENIA treats CLOZAPINE,128,44,,140,53,treats,1,908255-FS1-2,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE,RO-may_treat
503460462,7/16/2014 13:22:11,,1324250232,7/16/2014 13:22:05,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,CLOZAPINE treats SCHIZOPHRENIA,128,44,,140,53,treats,1,908255-FS1-2,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE,RO-may_treat
503460462,7/16/2014 13:29:03,,1324253100,7/16/2014 13:28:22,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,CLOZAPINE treats SCHIZOPHRENIA,128,44,,140,53,treats,1,908255-FS1-2,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE,RO-may_treat
503460462,7/16/2014 13:51:20,,1324261590,7/16/2014 13:50:45,instagc,0.7333,13763729,USA,"","",75.182.89.225,CLOZAPINE treats SCHIZOPHRENIA,128,44,,140,53,treats,1,908255-FS1-2,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE,RO-may_treat
503460462,7/16/2014 15:15:20,,1324293694,7/16/2014 15:15:05,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,CLOZAPINE treats SCHIZOPHRENIA,128,44,,140,53,treats,1,908255-FS1-2,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE,RO-may_treat
503460462,7/16/2014 16:38:43,,1324329929,7/16/2014 16:38:19,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,CLOZAPINE treats SCHIZOPHRENIA,128,44,,140,53,treats,1,908255-FS1-2,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE but not the typical APD haloperidol, improve some aspects of cognition in SCHIZOPHRENIA",SCHIZOPHRENIA,CLOZAPINE,RO-may_treat
503460463,7/16/2014 13:22:23,,1324250290,7/16/2014 13:22:13,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,FREE LUNG CELLS is location of BRONCHIAL CARCINOMA,265,289,,279,308,is location of,0.38490017945975,902226-FS1-9,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA,RO-disease_has_primary_anatomic_site
503460463,7/16/2014 13:30:14,,1324253592,7/16/2014 13:29:08,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,FREE LUNG CELLS is location of BRONCHIAL CARCINOMA,265,289,,279,308,is location of,0.38490017945975,902226-FS1-9,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA,RO-disease_has_primary_anatomic_site
503460463,7/16/2014 14:32:07,,1324278476,7/16/2014 14:31:45,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,FREE LUNG CELLS is location of BRONCHIAL CARCINOMA,265,289,,279,308,is location of,0.38490017945975,902226-FS1-9,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA,RO-disease_has_primary_anatomic_site
503460463,7/16/2014 15:09:54,,1324291943,7/16/2014 15:09:48,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,FREE LUNG CELLS is location of BRONCHIAL CARCINOMA,265,289,,279,308,is location of,0.38490017945975,902226-FS1-9,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA,RO-disease_has_primary_anatomic_site
503460463,7/16/2014 15:36:24,,1324300531,7/16/2014 15:36:17,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,BRONCHIAL CARCINOMA is location of FREE LUNG CELLS,265,289,,279,308,is location of,0.38490017945975,902226-FS1-9,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA,RO-disease_has_primary_anatomic_site
503460463,7/16/2014 17:09:43,,1324341287,7/16/2014 17:09:08,clixsense,0.5952,19638651,USA,"","",173.23.121.63,FREE LUNG CELLS is location of BRONCHIAL CARCINOMA,265,289,,279,308,is location of,0.38490017945975,902226-FS1-9,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA,RO-disease_has_primary_anatomic_site
503460463,7/16/2014 17:18:03,,1324343864,7/16/2014 17:17:32,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,FREE LUNG CELLS is location of BRONCHIAL CARCINOMA,265,289,,279,308,is location of,0.38490017945975,902226-FS1-9,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of FREE LUNG CELLS; and in BRONCHIAL CARCINOMA to investigate local immune responses to the tumour.",FREE LUNG CELLS,BRONCHIAL CARCINOMA,RO-disease_has_primary_anatomic_site
503460464,7/16/2014 13:06:39,,1324244014,7/16/2014 13:06:17,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,IMMEDIATE RELEASE LEVODOPA treats PD,278,213,,279,239,treats,0.866025403784439,907810-FS1-2,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA,RO-may_treat
503460464,7/16/2014 13:14:31,,1324247195,7/16/2014 13:14:16,instagc,0.7083,18960682,GBR,"","",86.29.147.112,IMMEDIATE RELEASE LEVODOPA treats PD,278,213,,279,239,treats,0.866025403784439,907810-FS1-2,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA,RO-may_treat
503460464,7/16/2014 13:16:21,,1324247850,7/16/2014 13:16:14,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,PD treats IMMEDIATE RELEASE LEVODOPA,278,213,,279,239,treats,0.866025403784439,907810-FS1-2,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA,RO-may_treat
503460464,7/16/2014 13:19:50,,1324249263,7/16/2014 13:19:41,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,PD treats IMMEDIATE RELEASE LEVODOPA,278,213,,279,239,treats,0.866025403784439,907810-FS1-2,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA,RO-may_treat
503460464,7/16/2014 13:19:57,,1324249302,7/16/2014 13:19:50,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,IMMEDIATE RELEASE LEVODOPA treats PD,278,213,,279,239,treats,0.866025403784439,907810-FS1-2,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA,RO-may_treat
503460464,7/16/2014 13:51:54,,1324261770,7/16/2014 13:51:21,instagc,0.7333,13763729,USA,"","",75.182.89.225,PD treats IMMEDIATE RELEASE LEVODOPA,278,213,,279,239,treats,0.866025403784439,907810-FS1-2,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA,RO-may_treat
503460464,7/16/2014 14:21:47,,1324274282,7/16/2014 14:21:27,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,IMMEDIATE RELEASE LEVODOPA treats PD,278,213,,279,239,treats,0.866025403784439,907810-FS1-2,STUDY SELECTION  English language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained release levodopa with IMMEDIATE RELEASE LEVODOPA in previously untreated patients with PD,PD,IMMEDIATE RELEASE LEVODOPA,RO-may_treat
503460465,7/16/2014 13:07:37,,1324244353,7/16/2014 13:07:08,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,SEIZURES causes EPILEPSY,387,400,,394,408,causes,0.668153104781061,904831-FS1-4,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY,RO-has_definitional_manifestation
503460465,7/16/2014 13:11:19,,1324245870,7/16/2014 13:11:09,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,SEIZURES causes EPILEPSY,387,400,,394,408,causes,0.668153104781061,904831-FS1-4,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY,RO-has_definitional_manifestation
503460465,7/16/2014 13:21:59,,1324250127,7/16/2014 13:21:24,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,no_relation,387,400,,394,408,causes,0.668153104781061,904831-FS1-4,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY,RO-has_definitional_manifestation
503460465,7/16/2014 13:33:56,,1324255338,7/16/2014 13:32:57,inboxpounds,0.65,22207998,GBR,N7,Banstead,86.3.88.5,EPILEPSY causes SEIZURES,387,400,,394,408,causes,0.668153104781061,904831-FS1-4,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY,RO-has_definitional_manifestation
503460465,7/16/2014 14:18:43,,1324273030,7/16/2014 14:18:25,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,EPILEPSY causes SEIZURES,387,400,,394,408,causes,0.668153104781061,904831-FS1-4,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY,RO-has_definitional_manifestation
503460465,7/16/2014 14:42:53,,1324282455,7/16/2014 14:42:18,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,EPILEPSY causes SEIZURES,387,400,,394,408,causes,0.668153104781061,904831-FS1-4,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY,RO-has_definitional_manifestation
503460465,7/16/2014 15:12:45,,1324292888,7/16/2014 15:12:27,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,SEIZURES causes EPILEPSY,387,400,,394,408,causes,0.668153104781061,904831-FS1-4,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of SEIZURES and EPILEPSY and the role of genetic factors in epilepsy.",SEIZURES,EPILEPSY,RO-has_definitional_manifestation
503460466,7/16/2014 13:08:55,,1324244924,7/16/2014 13:08:30,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,EXTRASKELETAL OSTEOCHONDROMA diagnosed by CALCIUM DEPOSITS,13,91,,28,119,diagnosed by,0.617213399848368,902718-FS1-13,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460466,7/16/2014 13:25:28,,1324251568,7/16/2014 13:25:05,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,EXTRASKELETAL OSTEOCHONDROMA diagnosed by CALCIUM DEPOSITS,13,91,,28,119,diagnosed by,0.617213399848368,902718-FS1-13,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460466,7/16/2014 14:17:57,,1324272697,7/16/2014 14:17:28,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,EXTRASKELETAL OSTEOCHONDROMA diagnosed by CALCIUM DEPOSITS,13,91,,28,119,diagnosed by,0.617213399848368,902718-FS1-13,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460466,7/16/2014 14:25:37,,1324275800,7/16/2014 14:25:16,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,CALCIUM DEPOSITS diagnosed by EXTRASKELETAL OSTEOCHONDROMA,13,91,,28,119,diagnosed by,0.617213399848368,902718-FS1-13,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460466,7/16/2014 14:44:55,,1324282968,7/16/2014 14:44:21,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,EXTRASKELETAL OSTEOCHONDROMA diagnosed by CALCIUM DEPOSITS,13,91,,28,119,diagnosed by,0.617213399848368,902718-FS1-13,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460466,7/16/2014 17:05:50,,1324339884,7/16/2014 17:05:27,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,EXTRASKELETAL OSTEOCHONDROMA diagnosed by CALCIUM DEPOSITS,13,91,,28,119,diagnosed by,0.617213399848368,902718-FS1-13,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460466,7/16/2014 17:47:16,,1324364502,7/16/2014 17:46:53,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,EXTRASKELETAL OSTEOCHONDROMA diagnosed by CALCIUM DEPOSITS,13,91,,28,119,diagnosed by,0.617213399848368,902718-FS1-13,"Two isolated CALCIUM DEPOSITS formed an encapsulated mass in the iliopsoas muscle, and the EXTRASKELETAL OSTEOCHONDROMA was diagnosed.",CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,RO-disease_may_have_finding
503460467,7/16/2014 13:06:39,,1324244011,7/16/2014 13:06:17,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,HEMOPHAGOCYTOSIS causes HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,159,196,,174,230,causes,0.452267016866645,901897-FS1-4,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460467,7/16/2014 13:08:08,,1324244606,7/16/2014 13:07:38,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS causes HEMOPHAGOCYTOSIS,159,196,,174,230,causes,0.452267016866645,901897-FS1-4,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460467,7/16/2014 13:08:55,,1324244923,7/16/2014 13:08:30,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,HEMOPHAGOCYTOSIS causes HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,159,196,,174,230,causes,0.452267016866645,901897-FS1-4,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460467,7/16/2014 13:31:31,,1324254210,7/16/2014 13:31:04,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,no_relation,159,196,,174,230,causes,0.452267016866645,901897-FS1-4,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460467,7/16/2014 13:34:20,,1324255516,7/16/2014 13:33:44,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,no_relation,159,196,,174,230,causes,0.452267016866645,901897-FS1-4,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460467,7/16/2014 15:14:48,,1324293558,7/16/2014 15:14:26,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,HEMOPHAGOCYTOSIS causes HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,159,196,,174,230,causes,0.452267016866645,901897-FS1-4,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460467,7/16/2014 17:08:42,,1324340936,7/16/2014 17:07:52,clixsense,0.5952,19638651,USA,"","",173.23.121.63,no_relation,159,196,,174,230,causes,0.452267016866645,901897-FS1-4,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with HEMOPHAGOCYTOSIS in the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.",HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,RO-disease_has_finding
503460468,7/16/2014 13:07:17,,1324244203,7/16/2014 13:06:48,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,HEPATOMA causes ASCITES,93,0,,99,8,causes,0.420084025208403,902957-FS1-4,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA,RO-disease_may_have_finding
503460468,7/16/2014 13:14:46,,1324247315,7/16/2014 13:14:31,instagc,0.7083,18960682,GBR,"","",86.29.147.112,no_relation,93,0,,99,8,causes,0.420084025208403,902957-FS1-4,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA,RO-disease_may_have_finding
503460468,7/16/2014 14:33:07,,1324278834,7/16/2014 14:32:44,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,ASCITES causes HEPATOMA,93,0,,99,8,causes,0.420084025208403,902957-FS1-4,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA,RO-disease_may_have_finding
503460468,7/16/2014 15:39:20,,1324301733,7/16/2014 15:38:21,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,no_relation,93,0,,99,8,causes,0.420084025208403,902957-FS1-4,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA,RO-disease_may_have_finding
503460468,7/16/2014 15:44:01,,1324303698,7/16/2014 15:43:53,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,ASCITES causes HEPATOMA,93,0,,99,8,causes,0.420084025208403,902957-FS1-4,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA,RO-disease_may_have_finding
503460468,7/16/2014 16:54:23,,1324336139,7/16/2014 16:53:34,clixsense,0.4786,6497991,USA,NC,Clinton,204.211.52.144,no_relation,93,0,,99,8,causes,0.420084025208403,902957-FS1-4,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA,RO-disease_may_have_finding
503460468,7/16/2014 17:06:30,,1324340098,7/16/2014 17:06:21,prodege,0.4233,12944140,GBR,C8,Croydon,92.21.8.174,ASCITES causes HEPATOMA,93,0,,99,8,causes,0.420084025208403,902957-FS1-4,"HEPATOMA in one patient was correctly identified by both methods, as well as the presence of ASCITES",ASCITES,HEPATOMA,RO-disease_may_have_finding
503460469,7/16/2014 13:10:10,,1324245401,7/16/2014 13:09:49,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,MOTION SICKNESS treats SCOPOLAMINE,45,116,,59,127,treats,0.866025403784439,907382-FS1-2,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE,RO-may_prevent
503460469,7/16/2014 13:16:08,,1324247776,7/16/2014 13:15:45,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,no_relation,45,116,,59,127,treats,0.866025403784439,907382-FS1-2,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE,RO-may_prevent
503460469,7/16/2014 15:43:36,,1324303494,7/16/2014 15:43:18,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,SCOPOLAMINE treats MOTION SICKNESS,45,116,,59,127,treats,0.866025403784439,907382-FS1-2,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE,RO-may_prevent
503460469,7/16/2014 16:38:18,,1324329609,7/16/2014 16:38:01,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,SCOPOLAMINE treats MOTION SICKNESS,45,116,,59,127,treats,0.866025403784439,907382-FS1-2,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE,RO-may_prevent
503460469,7/16/2014 17:27:09,,1324347277,7/16/2014 17:26:49,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,SCOPOLAMINE treats MOTION SICKNESS,45,116,,59,127,treats,0.866025403784439,907382-FS1-2,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE,RO-may_prevent
503460469,7/16/2014 17:46:52,,1324364020,7/16/2014 17:46:31,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,SCOPOLAMINE treats MOTION SICKNESS,45,116,,59,127,treats,0.866025403784439,907382-FS1-2,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE,RO-may_prevent
503460469,7/16/2014 18:01:51,,1324379718,7/16/2014 18:01:29,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,SCOPOLAMINE treats MOTION SICKNESS,45,116,,59,127,treats,0.866025403784439,907382-FS1-2,"Transdermal scopolamine provides significant MOTION SICKNESS protection, similar in extent to that provided by oral SCOPOLAMINE or dimenhydrinate.",MOTION SICKNESS,SCOPOLAMINE,RO-may_prevent
503460470,7/16/2014 13:18:28,,1324248715,7/16/2014 13:18:13,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,LOW MOLECULAR WEIGHT HEPARIN treats UNSTABLE ANGINA,77,45,,91,73,treats,0.976187060183953,908115-FS1-2,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN,RO-may_treat
503460470,7/16/2014 13:23:49,,1324250780,7/16/2014 13:23:25,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,LOW MOLECULAR WEIGHT HEPARIN treats UNSTABLE ANGINA,77,45,,91,73,treats,0.976187060183953,908115-FS1-2,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN,RO-may_treat
503460470,7/16/2014 14:27:21,,1324276390,7/16/2014 14:26:57,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,UNSTABLE ANGINA treats LOW MOLECULAR WEIGHT HEPARIN,77,45,,91,73,treats,0.976187060183953,908115-FS1-2,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN,RO-may_treat
503460470,7/16/2014 14:45:58,,1324283205,7/16/2014 14:45:33,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,LOW MOLECULAR WEIGHT HEPARIN treats UNSTABLE ANGINA,77,45,,91,73,treats,0.976187060183953,908115-FS1-2,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN,RO-may_treat
503460470,7/16/2014 17:05:50,,1324339883,7/16/2014 17:05:27,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,UNSTABLE ANGINA treats LOW MOLECULAR WEIGHT HEPARIN,77,45,,91,73,treats,0.976187060183953,908115-FS1-2,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN,RO-may_treat
503460470,7/16/2014 17:06:20,,1324340008,7/16/2014 17:06:14,prodege,0.4233,12944140,GBR,C8,Croydon,92.21.8.174,UNSTABLE ANGINA treats LOW MOLECULAR WEIGHT HEPARIN,77,45,,91,73,treats,0.976187060183953,908115-FS1-2,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN,RO-may_treat
503460470,7/16/2014 17:47:16,,1324364503,7/16/2014 17:46:53,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,LOW MOLECULAR WEIGHT HEPARIN treats UNSTABLE ANGINA,77,45,,91,73,treats,0.976187060183953,908115-FS1-2,The indications and length of treatment with LOW MOLECULAR WEIGHT HEPARIN in UNSTABLE ANGINA patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,UNSTABLE ANGINA,LOW MOLECULAR WEIGHT HEPARIN,RO-may_treat
503460471,7/16/2014 13:14:01,,1324246992,7/16/2014 13:13:38,instagc,0.7083,18960682,GBR,"","",86.29.147.112,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,230,207,,249,217,causes,0.462910049886276,906095-FS1-4,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460471,7/16/2014 13:19:24,,1324249067,7/16/2014 13:19:15,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,230,207,,249,217,causes,0.462910049886276,906095-FS1-4,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460471,7/16/2014 13:19:49,,1324249265,7/16/2014 13:19:43,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,230,207,,249,217,causes,0.462910049886276,906095-FS1-4,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460471,7/16/2014 13:35:46,,1324256065,7/16/2014 13:35:32,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,230,207,,249,217,causes,0.462910049886276,906095-FS1-4,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460471,7/16/2014 14:31:03,,1324278110,7/16/2014 14:30:13,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,no_relation,230,207,,249,217,causes,0.462910049886276,906095-FS1-4,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460471,7/16/2014 15:36:24,,1324300532,7/16/2014 15:36:17,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,230,207,,249,217,causes,0.462910049886276,906095-FS1-4,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460471,7/16/2014 15:43:17,,1324303300,7/16/2014 15:42:59,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,BCL 2 GENE causes FOLLICULAR LYMPHOMAS,230,207,,249,217,causes,0.462910049886276,906095-FS1-4,"This growth enhancement was also seen in cells transfected with the BCL 2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL 2 GENE observed in FOLLICULAR LYMPHOMAS with the t(14;18) translocation.",FOLLICULAR LYMPHOMAS,BCL 2 GENE,RO-has_manifestation
503460472,7/16/2014 13:07:09,,1324244162,7/16/2014 13:06:45,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,61,121,,81,138,causes,0.938314863256836,902720-FS1-4,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES,RO-disease_may_have_finding
503460472,7/16/2014 13:38:24,,1324257035,7/16/2014 13:38:01,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,61,121,,81,138,causes,0.938314863256836,902720-FS1-4,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES,RO-disease_may_have_finding
503460472,7/16/2014 13:52:46,,1324262110,7/16/2014 13:52:18,instagc,0.7333,13763729,USA,"","",75.182.89.225,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,61,121,,81,138,causes,0.938314863256836,902720-FS1-4,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES,RO-disease_may_have_finding
503460472,7/16/2014 14:46:27,,1324283368,7/16/2014 14:45:59,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,61,121,,81,138,causes,0.938314863256836,902720-FS1-4,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES,RO-disease_may_have_finding
503460472,7/16/2014 15:43:36,,1324303490,7/16/2014 15:43:18,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,61,121,,81,138,causes,0.938314863256836,902720-FS1-4,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES,RO-disease_may_have_finding
503460472,7/16/2014 16:38:56,,1324330048,7/16/2014 16:38:45,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,61,121,,81,138,causes,0.938314863256836,902720-FS1-4,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES,RO-disease_may_have_finding
503460472,7/16/2014 16:39:49,,1324330523,7/16/2014 16:39:26,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,SPINAL METASTASES causes PATHOLOGICAL FRACTURE,61,121,,81,138,causes,0.938314863256836,902720-FS1-4,"However, radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE which is an important complication of SPINAL METASTASES",PATHOLOGICAL FRACTURE,SPINAL METASTASES,RO-disease_may_have_finding
503460473,7/16/2014 13:12:25,,1324246289,7/16/2014 13:11:55,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,no_relation,22,22,,43,54,causes,0.771516749810459,903703-FS1-4,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460473,7/16/2014 13:23:23,,1324250610,7/16/2014 13:23:03,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,VARICELLA ZOSTER VIRUS causes VARICELLA ZOSTER VIRUS INFECTION,22,22,,43,54,causes,0.771516749810459,903703-FS1-4,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460473,7/16/2014 13:52:17,,1324261890,7/16/2014 13:51:55,instagc,0.7333,13763729,USA,"","",75.182.89.225,VARICELLA ZOSTER VIRUS causes VARICELLA ZOSTER VIRUS INFECTION,22,22,,43,54,causes,0.771516749810459,903703-FS1-4,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460473,7/16/2014 14:17:04,,1324272333,7/16/2014 14:16:43,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,no_relation,22,22,,43,54,causes,0.771516749810459,903703-FS1-4,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460473,7/16/2014 14:26:21,,1324276075,7/16/2014 14:25:22,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,VARICELLA ZOSTER VIRUS causes VARICELLA ZOSTER VIRUS INFECTION,22,22,,43,54,causes,0.771516749810459,903703-FS1-4,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460473,7/16/2014 14:45:58,,1324283210,7/16/2014 14:45:33,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,VARICELLA ZOSTER VIRUS causes VARICELLA ZOSTER VIRUS INFECTION,22,22,,43,54,causes,0.771516749810459,903703-FS1-4,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460473,7/16/2014 15:09:33,,1324291833,7/16/2014 15:09:22,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,VARICELLA ZOSTER VIRUS INFECTION causes VARICELLA ZOSTER VIRUS,22,22,,43,54,causes,0.771516749810459,903703-FS1-4,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460474,7/16/2014 13:06:26,,1324243908,7/16/2014 13:06:05,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,S PANAMA BACTEREMIA treats BACTERIA,32,71,,39,90,treats,0.365148371670111,903807-FS1-2,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460474,7/16/2014 13:11:05,,1324245747,7/16/2014 13:10:52,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,BACTERIA treats S PANAMA BACTEREMIA,32,71,,39,90,treats,0.365148371670111,903807-FS1-2,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460474,7/16/2014 13:17:08,,1324248162,7/16/2014 13:16:45,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,S PANAMA BACTEREMIA treats BACTERIA,32,71,,39,90,treats,0.365148371670111,903807-FS1-2,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460474,7/16/2014 13:19:25,,1324249072,7/16/2014 13:18:57,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,S PANAMA BACTEREMIA treats BACTERIA,32,71,,39,90,treats,0.365148371670111,903807-FS1-2,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460474,7/16/2014 14:22:21,,1324274530,7/16/2014 14:21:48,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,S PANAMA BACTEREMIA treats BACTERIA,32,71,,39,90,treats,0.365148371670111,903807-FS1-2,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460474,7/16/2014 14:28:27,,1324276889,7/16/2014 14:27:35,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,no_relation,32,71,,39,90,treats,0.365148371670111,903807-FS1-2,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460474,7/16/2014 15:42:50,,1324303129,7/16/2014 15:42:22,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,S PANAMA BACTEREMIA treats BACTERIA,32,71,,39,90,treats,0.365148371670111,903807-FS1-2,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460475,7/16/2014 13:29:24,,1324253261,7/16/2014 13:28:25,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,PAROXETINE treats MAJOR DEPRESSION,36,118,,51,128,treats,0.997054485501582,907618-FS1-2,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE,RO-may_treat
503460475,7/16/2014 13:32:56,,1324254846,7/16/2014 13:31:54,inboxpounds,0.65,22207998,GBR,N7,Banstead,86.3.88.5,PAROXETINE treats MAJOR DEPRESSION,36,118,,51,128,treats,0.997054485501582,907618-FS1-2,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE,RO-may_treat
503460475,7/16/2014 13:34:20,,1324255517,7/16/2014 13:33:44,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,PAROXETINE treats MAJOR DEPRESSION,36,118,,51,128,treats,0.997054485501582,907618-FS1-2,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE,RO-may_treat
503460475,7/16/2014 13:34:39,,1324255685,7/16/2014 13:34:23,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,PAROXETINE treats MAJOR DEPRESSION,36,118,,51,128,treats,0.997054485501582,907618-FS1-2,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE,RO-may_treat
503460475,7/16/2014 14:26:02,,1324275954,7/16/2014 14:25:39,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,PAROXETINE treats MAJOR DEPRESSION,36,118,,51,128,treats,0.997054485501582,907618-FS1-2,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE,RO-may_treat
503460475,7/16/2014 14:53:56,,1324285678,7/16/2014 14:53:38,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,no_relation,36,118,,51,128,treats,0.997054485501582,907618-FS1-2,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE,RO-may_treat
503460475,7/16/2014 15:34:16,,1324299722,7/16/2014 15:33:48,instagc,0.7538,19636746,USA,NY,Andover,192.182.216.225,PAROXETINE treats MAJOR DEPRESSION,36,118,,51,128,treats,0.997054485501582,907618-FS1-2,"CONCLUSIONS  In older patients with MAJOR DEPRESSION who responded to treatment, long term maintenance treatment with PAROXETINE prevented recurrence of depression.",MAJOR DEPRESSION,PAROXETINE,RO-may_treat
503460476,7/16/2014 13:06:47,,1324244039,7/16/2014 13:06:27,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,BONE is location of OSTEOPOROSIS,56,0,,59,12,is location of,0.943879807448539,902388-FS1-9,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503460476,7/16/2014 13:08:08,,1324244605,7/16/2014 13:07:38,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,OSTEOPOROSIS is location of BONE,56,0,,59,12,is location of,0.943879807448539,902388-FS1-9,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503460476,7/16/2014 14:32:43,,1324278714,7/16/2014 14:32:08,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,OSTEOPOROSIS is location of BONE,56,0,,59,12,is location of,0.943879807448539,902388-FS1-9,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503460476,7/16/2014 15:37:19,,1324300849,7/16/2014 15:37:08,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,BONE is location of OSTEOPOROSIS,56,0,,59,12,is location of,0.943879807448539,902388-FS1-9,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503460476,7/16/2014 15:44:18,,1324303810,7/16/2014 15:44:02,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,BONE is location of OSTEOPOROSIS,56,0,,59,12,is location of,0.943879807448539,902388-FS1-9,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503460476,7/16/2014 17:09:43,,1324341288,7/16/2014 17:09:08,clixsense,0.5952,19638651,USA,"","",173.23.121.63,BONE is location of OSTEOPOROSIS,56,0,,59,12,is location of,0.943879807448539,902388-FS1-9,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503460476,7/16/2014 18:02:11,,1324380029,7/16/2014 18:01:51,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,BONE is location of OSTEOPOROSIS,56,0,,59,12,is location of,0.943879807448539,902388-FS1-9,OSTEOPOROSIS medications can exert favorable effects on BONE size and cortical thickness.,BONE,OSTEOPOROSIS,RO-disease_has_primary_anatomic_site
503460477,7/16/2014 13:18:13,,1324248629,7/16/2014 13:17:32,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,LSIL causes HIGH GRADE CERVICAL DYSPLASIA,96,69,,124,73,causes,0.721687836487032,901864-FS1-4,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL,RO-disease_has_finding
503460477,7/16/2014 13:23:02,,1324250492,7/16/2014 13:22:08,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,LSIL causes HIGH GRADE CERVICAL DYSPLASIA,96,69,,124,73,causes,0.721687836487032,901864-FS1-4,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL,RO-disease_has_finding
503460477,7/16/2014 13:31:31,,1324254211,7/16/2014 13:31:04,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,LSIL causes HIGH GRADE CERVICAL DYSPLASIA,96,69,,124,73,causes,0.721687836487032,901864-FS1-4,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL,RO-disease_has_finding
503460477,7/16/2014 14:55:44,,1324286316,7/16/2014 14:55:12,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,no_relation,96,69,,124,73,causes,0.721687836487032,901864-FS1-4,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL,RO-disease_has_finding
503460477,7/16/2014 17:06:15,,1324339982,7/16/2014 17:05:50,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,LSIL causes HIGH GRADE CERVICAL DYSPLASIA,96,69,,124,73,causes,0.721687836487032,901864-FS1-4,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL,RO-disease_has_finding
503460477,7/16/2014 17:18:45,,1324344019,7/16/2014 17:17:45,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,HIGH GRADE CERVICAL DYSPLASIA causes LSIL,96,69,,124,73,causes,0.721687836487032,901864-FS1-4,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL,RO-disease_has_finding
503460477,7/16/2014 17:44:40,,1324361620,7/16/2014 17:44:09,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,LSIL causes HIGH GRADE CERVICAL DYSPLASIA,96,69,,124,73,causes,0.721687836487032,901864-FS1-4,"More recent evidence suggests that HIV positive women with ASC US or LSIL have similar rates of HIGH GRADE CERVICAL DYSPLASIA to HIV negative women, although a trend towards increased rates of CIN II or worse was observed among women with worsening immunosuppression ( 74.",HIGH GRADE CERVICAL DYSPLASIA,LSIL,RO-disease_has_finding
503460478,7/16/2014 13:07:09,,1324244163,7/16/2014 13:06:45,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,233,257,,255,269,treats,0.50709255283711,907380-FS1-2,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,RO-may_prevent
503460478,7/16/2014 13:08:02,,1324244550,7/16/2014 13:07:30,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,no_relation,233,257,,255,269,treats,0.50709255283711,907380-FS1-2,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,RO-may_prevent
503460478,7/16/2014 13:10:10,,1324245396,7/16/2014 13:09:49,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,233,257,,255,269,treats,0.50709255283711,907380-FS1-2,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,RO-may_prevent
503460478,7/16/2014 13:25:04,,1324251368,7/16/2014 13:24:48,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,233,257,,255,269,treats,0.50709255283711,907380-FS1-2,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,RO-may_prevent
503460478,7/16/2014 13:31:53,,1324254412,7/16/2014 13:30:26,inboxpounds,0.65,22207998,GBR,N7,Banstead,86.3.88.5,DISOPYRAMIDE treats VENTRICULAR TACHYCARDIA,233,257,,255,269,treats,0.50709255283711,907380-FS1-2,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,RO-may_prevent
503460478,7/16/2014 14:31:03,,1324278105,7/16/2014 14:30:13,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,no_relation,233,257,,255,269,treats,0.50709255283711,907380-FS1-2,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,RO-may_prevent
503460478,7/16/2014 15:36:47,,1324300659,7/16/2014 15:36:25,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,no_relation,233,257,,255,269,treats,0.50709255283711,907380-FS1-2,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of VENTRICULAR TACHYCARDIA DISOPYRAMIDE was capable to interrupt the arrhythmias.",VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,RO-may_prevent
503460479,7/16/2014 13:13:37,,1324246826,7/16/2014 13:13:26,instagc,0.7083,18960682,GBR,"","",86.29.147.112,ASCITES is location of HEPATOMA,58,75,,64,83,is location of,0.78086880944303,902643-FS1-9,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460479,7/16/2014 13:16:41,,1324248033,7/16/2014 13:16:18,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,ASCITES is location of HEPATOMA,58,75,,64,83,is location of,0.78086880944303,902643-FS1-9,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460479,7/16/2014 13:20:03,,1324249365,7/16/2014 13:19:57,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,HEPATOMA is location of ASCITES,58,75,,64,83,is location of,0.78086880944303,902643-FS1-9,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460479,7/16/2014 13:32:50,,1324254803,7/16/2014 13:32:18,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,ASCITES is location of HEPATOMA,58,75,,64,83,is location of,0.78086880944303,902643-FS1-9,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460479,7/16/2014 13:38:00,,1324256866,7/16/2014 13:37:36,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,no_relation,58,75,,64,83,is location of,0.78086880944303,902643-FS1-9,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460479,7/16/2014 14:28:27,,1324276885,7/16/2014 14:27:35,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,ASCITES is location of HEPATOMA,58,75,,64,83,is location of,0.78086880944303,902643-FS1-9,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460479,7/16/2014 15:02:43,,1324289129,7/16/2014 15:02:10,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,HEPATOMA is location of ASCITES,58,75,,64,83,is location of,0.78086880944303,902643-FS1-9,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460480,7/16/2014 13:08:45,,1324244869,7/16/2014 13:08:22,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,ANTIARRHYTHMIC DRUG EFFICACY treats ARRHYTHMIAS,213,88,,223,116,treats,0.762492851663023,907090-FS1-2,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460480,7/16/2014 13:15:33,,1324247599,7/16/2014 13:15:02,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,ARRHYTHMIAS treats ANTIARRHYTHMIC DRUG EFFICACY,213,88,,223,116,treats,0.762492851663023,907090-FS1-2,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460480,7/16/2014 13:52:46,,1324262111,7/16/2014 13:52:18,instagc,0.7333,13763729,USA,"","",75.182.89.225,no_relation,213,88,,223,116,treats,0.762492851663023,907090-FS1-2,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460480,7/16/2014 14:26:21,,1324276066,7/16/2014 14:25:22,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,no_relation,213,88,,223,116,treats,0.762492851663023,907090-FS1-2,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460480,7/16/2014 14:32:43,,1324278715,7/16/2014 14:32:08,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,ANTIARRHYTHMIC DRUG EFFICACY treats ARRHYTHMIAS,213,88,,223,116,treats,0.762492851663023,907090-FS1-2,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460480,7/16/2014 14:44:55,,1324282967,7/16/2014 14:44:21,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,ANTIARRHYTHMIC DRUG EFFICACY treats ARRHYTHMIAS,213,88,,223,116,treats,0.762492851663023,907090-FS1-2,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460480,7/16/2014 15:14:48,,1324293559,7/16/2014 15:14:26,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,ANTIARRHYTHMIC DRUG EFFICACY treats ARRHYTHMIAS,213,88,,223,116,treats,0.762492851663023,907090-FS1-2,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460481,7/16/2014 13:50:13,,1324261172,7/16/2014 13:49:35,instagc,0.7333,13763729,USA,"","",75.182.89.225,no_relation,0,42,,5,51,is location of,0.959403223600247,905124-FS1-9,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS,RO-has_finding_site
503460481,7/16/2014 15:44:41,,1324304006,7/16/2014 15:44:19,neodev,0.6659,27597779,CAN,AB,Calgary,72.29.251.209,LENSES is location of CATARACTS,0,42,,5,51,is location of,0.959403223600247,905124-FS1-9,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS,RO-has_finding_site
503460481,7/16/2014 16:38:18,,1324329621,7/16/2014 16:38:01,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,CATARACTS is location of LENSES,0,42,,5,51,is location of,0.959403223600247,905124-FS1-9,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS,RO-has_finding_site
503460481,7/16/2014 16:40:24,,1324330876,7/16/2014 16:40:11,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,CATARACTS is location of LENSES,0,42,,5,51,is location of,0.959403223600247,905124-FS1-9,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS,RO-has_finding_site
503460481,7/16/2014 17:04:59,,1324339733,7/16/2014 17:04:39,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,LENSES is location of CATARACTS,0,42,,5,51,is location of,0.959403223600247,905124-FS1-9,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS,RO-has_finding_site
503460481,7/16/2014 17:06:30,,1324340100,7/16/2014 17:06:21,prodege,0.4233,12944140,GBR,C8,Croydon,92.21.8.174,LENSES is location of CATARACTS,0,42,,5,51,is location of,0.959403223600247,905124-FS1-9,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS,RO-has_finding_site
503460481,7/16/2014 17:19:28,,1324344228,7/16/2014 17:18:47,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,CATARACTS is location of LENSES,0,42,,5,51,is location of,0.959403223600247,905124-FS1-9,LENSES were examined with a slit lamp and CATARACTS were graded on a scale of 1+ to 4+.,LENSES,CATARACTS,RO-has_finding_site
503460482,7/16/2014 13:25:28,,1324251569,7/16/2014 13:25:05,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,no_relation,91,63,,109,73,causes,0.848528137423857,906133-FS1-4,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460482,7/16/2014 13:38:48,,1324257189,7/16/2014 13:38:25,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,no_relation,91,63,,109,73,causes,0.848528137423857,906133-FS1-4,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460482,7/16/2014 13:51:20,,1324261589,7/16/2014 13:50:45,instagc,0.7333,13763729,USA,"","",75.182.89.225,BCL 2 GENE causes FOLLICULAR LYMPHOMA,91,63,,109,73,causes,0.848528137423857,906133-FS1-4,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460482,7/16/2014 15:10:01,,1324291965,7/16/2014 15:09:55,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,FOLLICULAR LYMPHOMA causes BCL 2 GENE,91,63,,109,73,causes,0.848528137423857,906133-FS1-4,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460482,7/16/2014 15:36:09,,1324300397,7/16/2014 15:35:58,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,BCL 2 GENE causes FOLLICULAR LYMPHOMA,91,63,,109,73,causes,0.848528137423857,906133-FS1-4,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460482,7/16/2014 15:49:08,,1324305822,7/16/2014 15:48:58,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,91,63,,109,73,causes,0.848528137423857,906133-FS1-4,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460482,7/16/2014 17:04:50,,1324339702,7/16/2014 17:04:22,prodege,0.4233,12944140,GBR,C8,Croydon,92.21.8.174,BCL 2 GENE causes FOLLICULAR LYMPHOMA,91,63,,109,73,causes,0.848528137423857,906133-FS1-4,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460483,7/16/2014 13:08:30,,1324244753,7/16/2014 13:07:55,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,RENAL LYMPHOMA causes PRIMARY LESION,108,157,,121,171,causes,0.522232967867094,901633-FS1-4,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA,RO-disease_has_finding
503460483,7/16/2014 13:24:19,,1324251007,7/16/2014 13:23:56,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,RENAL LYMPHOMA causes PRIMARY LESION,108,157,,121,171,causes,0.522232967867094,901633-FS1-4,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA,RO-disease_has_finding
503460483,7/16/2014 14:30:30,,1324277855,7/16/2014 14:29:50,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,RENAL LYMPHOMA causes PRIMARY LESION,108,157,,121,171,causes,0.522232967867094,901633-FS1-4,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA,RO-disease_has_finding
503460483,7/16/2014 15:09:47,,1324291898,7/16/2014 15:09:42,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,RENAL LYMPHOMA causes PRIMARY LESION,108,157,,121,171,causes,0.522232967867094,901633-FS1-4,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA,RO-disease_has_finding
503460483,7/16/2014 15:36:47,,1324300658,7/16/2014 15:36:25,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,no_relation,108,157,,121,171,causes,0.522232967867094,901633-FS1-4,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA,RO-disease_has_finding
503460483,7/16/2014 15:39:20,,1324301732,7/16/2014 15:38:21,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,no_relation,108,157,,121,171,causes,0.522232967867094,901633-FS1-4,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA,RO-disease_has_finding
503460483,7/16/2014 15:49:30,,1324306004,7/16/2014 15:49:09,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,RENAL LYMPHOMA causes PRIMARY LESION,108,157,,121,171,causes,0.522232967867094,901633-FS1-4,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a PRIMARY LESION; almost all patients with primary RENAL LYMPHOMA will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,PRIMARY LESION,RENAL LYMPHOMA,RO-disease_has_finding
503460484,7/16/2014 13:14:35,,1324247237,7/16/2014 13:14:09,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,VERRUCA PLANA TYPE LESION causes HYPERKERATOSIS,115,76,,128,101,causes,0.529812942826018,901815-FS1-4,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION,RO-disease_has_finding
503460484,7/16/2014 13:19:42,,1324249201,7/16/2014 13:19:35,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,VERRUCA PLANA TYPE LESION causes HYPERKERATOSIS,115,76,,128,101,causes,0.529812942826018,901815-FS1-4,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION,RO-disease_has_finding
503460484,7/16/2014 13:22:48,,1324250413,7/16/2014 13:22:23,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,no_relation,115,76,,128,101,causes,0.529812942826018,901815-FS1-4,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION,RO-disease_has_finding
503460484,7/16/2014 13:23:02,,1324250493,7/16/2014 13:22:08,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,VERRUCA PLANA TYPE LESION causes HYPERKERATOSIS,115,76,,128,101,causes,0.529812942826018,901815-FS1-4,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION,RO-disease_has_finding
503460484,7/16/2014 13:24:12,,1324250962,7/16/2014 13:23:29,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,no_relation,115,76,,128,101,causes,0.529812942826018,901815-FS1-4,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION,RO-disease_has_finding
503460484,7/16/2014 13:33:43,,1324255240,7/16/2014 13:33:22,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,no_relation,115,76,,128,101,causes,0.529812942826018,901815-FS1-4,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION,RO-disease_has_finding
503460484,7/16/2014 14:36:30,,1324280354,7/16/2014 14:35:27,vivatic,0.4524,19526833,GBR,K2,Oxford,86.24.196.187,no_relation,115,76,,128,101,causes,0.529812942826018,901815-FS1-4,The classic histologic presentation of epidermodysplasia verruciformis is a VERRUCA PLANA TYPE LESION with minimal HYPERKERATOSIS and acanthotic areas where the cells contain perinuclear halos and blue gray pallor.,HYPERKERATOSIS,VERRUCA PLANA TYPE LESION,RO-disease_has_finding
503460485,7/16/2014 13:07:29,,1324244279,7/16/2014 13:06:41,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,VARICELLA ZOSTER VIRUS diagnosed by VARICELLA ZOSTER VIRUS INFECTION,22,22,,43,54,diagnosed by,0.617213399848368,903703-FS1-13,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460485,7/16/2014 13:19:05,,1324248948,7/16/2014 13:18:59,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,VARICELLA ZOSTER VIRUS INFECTION diagnosed by VARICELLA ZOSTER VIRUS,22,22,,43,54,diagnosed by,0.617213399848368,903703-FS1-13,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460485,7/16/2014 13:26:17,,1324251884,7/16/2014 13:25:35,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,VARICELLA ZOSTER VIRUS diagnosed by VARICELLA ZOSTER VIRUS INFECTION,22,22,,43,54,diagnosed by,0.617213399848368,903703-FS1-13,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460485,7/16/2014 13:32:17,,1324254606,7/16/2014 13:31:33,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,VARICELLA ZOSTER VIRUS INFECTION diagnosed by VARICELLA ZOSTER VIRUS,22,22,,43,54,diagnosed by,0.617213399848368,903703-FS1-13,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460485,7/16/2014 14:44:19,,1324282834,7/16/2014 14:43:50,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,VARICELLA ZOSTER VIRUS INFECTION diagnosed by VARICELLA ZOSTER VIRUS,22,22,,43,54,diagnosed by,0.617213399848368,903703-FS1-13,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460485,7/16/2014 14:55:11,,1324286105,7/16/2014 14:54:46,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,VARICELLA ZOSTER VIRUS diagnosed by VARICELLA ZOSTER VIRUS INFECTION,22,22,,43,54,diagnosed by,0.617213399848368,903703-FS1-13,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460485,7/16/2014 15:35:50,,1324300296,7/16/2014 15:35:07,instagc,0.7538,19636746,USA,NY,Andover,192.182.216.225,no_relation,22,22,,43,54,diagnosed by,0.617213399848368,903703-FS1-13,Serologic evidence of VARICELLA ZOSTER VIRUS INFECTION was measured by enzyme immunoassay of VARICELLA ZOSTER VIRUS specific IgG antibody.,VARICELLA ZOSTER VIRUS,VARICELLA ZOSTER VIRUS INFECTION,RO-has_causative_agent
503460486,7/16/2014 14:17:26,,1324272494,7/16/2014 14:17:06,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,no_relation,58,75,,64,83,causes,0.312347523777212,902643-FS1-4,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460486,7/16/2014 14:47:36,,1324283732,7/16/2014 14:46:28,clixsense,0.6742,28324391,NLD,11,Hazerswoude-rijndijk,94.208.82.215,HEPATOMA causes ASCITES,58,75,,64,83,causes,0.312347523777212,902643-FS1-4,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460486,7/16/2014 15:15:03,,1324293618,7/16/2014 15:14:50,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,ASCITES causes HEPATOMA,58,75,,64,83,causes,0.312347523777212,902643-FS1-4,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460486,7/16/2014 17:04:50,,1324339705,7/16/2014 17:04:22,prodege,0.4233,12944140,GBR,C8,Croydon,92.21.8.174,ASCITES causes HEPATOMA,58,75,,64,83,causes,0.312347523777212,902643-FS1-4,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460486,7/16/2014 17:17:31,,1324343695,7/16/2014 17:17:10,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,HEPATOMA causes ASCITES,58,75,,64,83,causes,0.312347523777212,902643-FS1-4,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460486,7/16/2014 18:01:28,,1324379287,7/16/2014 18:00:40,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,ASCITES causes HEPATOMA,58,75,,64,83,causes,0.312347523777212,902643-FS1-4,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460486,7/16/2014 18:07:59,,1324385883,7/16/2014 18:07:28,clixsense,0.4083,6451515,USA,MN,Minneapolis,75.144.36.177,HEPATOMA causes ASCITES,58,75,,64,83,causes,0.312347523777212,902643-FS1-4,The activities of nucleoside diphosphatase in various rat ASCITES cells of HEPATOMA and fetal and neonatal rat liver were much lower than that of normal adult rat liver.,ASCITES,HEPATOMA,RO-disease_may_have_finding
503460487,7/16/2014 13:15:01,,1324247413,7/16/2014 13:14:37,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,no_relation,44,116,,67,125,causes,0.316227766016838,907551-FS1-4,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460487,7/16/2014 13:26:46,,1324252132,7/16/2014 13:26:18,clixsense,0.8056,15189335,GBR,I9,Bury Saint Edmunds,81.155.129.231,no_relation,44,116,,67,125,causes,0.316227766016838,907551-FS1-4,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460487,7/16/2014 13:34:53,,1324255752,7/16/2014 13:34:21,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,no_relation,44,116,,67,125,causes,0.316227766016838,907551-FS1-4,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460487,7/16/2014 15:00:10,,1324288004,7/16/2014 14:59:13,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,ENALAPRIL causes CONGESTIVE HEART FAILURE,44,116,,67,125,causes,0.316227766016838,907551-FS1-4,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460487,7/16/2014 15:37:19,,1324300848,7/16/2014 15:37:08,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,no_relation,44,116,,67,125,causes,0.316227766016838,907551-FS1-4,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460487,7/16/2014 16:53:33,,1324335890,7/16/2014 16:52:49,clixsense,0.4786,6497991,USA,NC,Clinton,204.211.52.144,ENALAPRIL causes CONGESTIVE HEART FAILURE,44,116,,67,125,causes,0.316227766016838,907551-FS1-4,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460487,7/16/2014 17:46:52,,1324364048,7/16/2014 17:46:31,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,CONGESTIVE HEART FAILURE causes ENALAPRIL,44,116,,67,125,causes,0.316227766016838,907551-FS1-4,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460488,7/16/2014 13:06:04,,1324243782,7/16/2014 13:05:50,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,SKIN is location of INTRADERMAL NEVUS,86,111,,89,128,is location of,0.566946709513841,905150-FS1-9,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS,RO-has_finding_site
503460488,7/16/2014 13:07:57,,1324244523,7/16/2014 13:07:36,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,SKIN is location of INTRADERMAL NEVUS,86,111,,89,128,is location of,0.566946709513841,905150-FS1-9,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS,RO-has_finding_site
503460488,7/16/2014 13:10:48,,1324245659,7/16/2014 13:10:38,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,SKIN is location of INTRADERMAL NEVUS,86,111,,89,128,is location of,0.566946709513841,905150-FS1-9,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS,RO-has_finding_site
503460488,7/16/2014 13:26:02,,1324251765,7/16/2014 13:25:31,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,SKIN is location of INTRADERMAL NEVUS,86,111,,89,128,is location of,0.566946709513841,905150-FS1-9,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS,RO-has_finding_site
503460488,7/16/2014 14:32:07,,1324278486,7/16/2014 14:31:45,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,INTRADERMAL NEVUS is location of SKIN,86,111,,89,128,is location of,0.566946709513841,905150-FS1-9,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS,RO-has_finding_site
503460488,7/16/2014 15:40:15,,1324302083,7/16/2014 15:39:35,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,INTRADERMAL NEVUS is location of SKIN,86,111,,89,128,is location of,0.566946709513841,905150-FS1-9,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS,RO-has_finding_site
503460488,7/16/2014 16:52:48,,1324335605,7/16/2014 16:51:39,clixsense,0.4786,6497991,USA,NC,Clinton,204.211.52.144,INTRADERMAL NEVUS is location of SKIN,86,111,,89,128,is location of,0.566946709513841,905150-FS1-9,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented SKIN sites [nonpigmented INTRADERMAL NEVUS neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",SKIN,INTRADERMAL NEVUS,RO-has_finding_site
503460489,7/16/2014 13:07:17,,1324244204,7/16/2014 13:06:48,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,44,116,,67,125,treats,0.790569415042095,907551-FS1-2,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460489,7/16/2014 13:13:25,,1324246715,7/16/2014 13:13:05,instagc,0.7083,18960682,GBR,"","",86.29.147.112,ENALAPRIL treats CONGESTIVE HEART FAILURE,44,116,,67,125,treats,0.790569415042095,907551-FS1-2,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460489,7/16/2014 13:19:39,,1324249166,7/16/2014 13:19:25,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,ENALAPRIL treats CONGESTIVE HEART FAILURE,44,116,,67,125,treats,0.790569415042095,907551-FS1-2,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460489,7/16/2014 13:21:23,,1324249871,7/16/2014 13:20:53,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,ENALAPRIL treats CONGESTIVE HEART FAILURE,44,116,,67,125,treats,0.790569415042095,907551-FS1-2,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460489,7/16/2014 13:38:48,,1324257188,7/16/2014 13:38:25,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,ENALAPRIL treats CONGESTIVE HEART FAILURE,44,116,,67,125,treats,0.790569415042095,907551-FS1-2,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460489,7/16/2014 15:36:15,,1324300451,7/16/2014 15:36:09,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,ENALAPRIL treats CONGESTIVE HEART FAILURE,44,116,,67,125,treats,0.790569415042095,907551-FS1-2,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460489,7/16/2014 17:17:22,,1324343613,7/16/2014 17:16:22,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,ENALAPRIL treats CONGESTIVE HEART FAILURE,44,116,,67,125,treats,0.790569415042095,907551-FS1-2,Effects of enalapril on mortality in severe CONGESTIVE HEART FAILURE: results of the cooperative North Scandinavian ENALAPRIL survival study (consensus.,CONGESTIVE HEART FAILURE,ENALAPRIL,RO-may_treat
503460490,7/16/2014 13:11:35,,1324245934,7/16/2014 13:11:22,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,ARRHYTHMIAS contraindicates ANTIARRHYTHMIC DRUG EFFICACY,213,88,,223,116,contraindicates,0.304997140665209,907090-FS1-10,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460490,7/16/2014 16:39:06,,1324330156,7/16/2014 16:38:57,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,ANTIARRHYTHMIC DRUG EFFICACY contraindicates ARRHYTHMIAS,213,88,,223,116,contraindicates,0.304997140665209,907090-FS1-10,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460490,7/16/2014 18:34:40,,1324404352,7/16/2014 18:34:31,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,no_relation,213,88,,223,116,contraindicates,0.304997140665209,907090-FS1-10,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460490,7/16/2014 18:48:19,,1324411496,7/16/2014 18:47:19,eup_slw,0.5873,28186528,USA,IN,Bloomington,74.204.124.9,ARRHYTHMIAS contraindicates ANTIARRHYTHMIC DRUG EFFICACY,213,88,,223,116,contraindicates,0.304997140665209,907090-FS1-10,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460490,7/16/2014 19:29:04,,1324434073,7/16/2014 19:28:24,clixsense,0.5333,6714657,USA,CT,Groton,71.235.184.32,ANTIARRHYTHMIC DRUG EFFICACY contraindicates ARRHYTHMIAS,213,88,,223,116,contraindicates,0.304997140665209,907090-FS1-10,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460490,7/16/2014 19:44:20,,1324441363,7/16/2014 19:43:28,prodege,0.3333,13391452,GBR,B7,Bristol,90.213.30.203,no_relation,213,88,,223,116,contraindicates,0.304997140665209,907090-FS1-10,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460490,7/16/2014 19:56:33,,1324447192,7/16/2014 19:56:19,neodev,0.4286,18755947,GBR,H2,Accrington,80.47.185.52,no_relation,213,88,,223,116,contraindicates,0.304997140665209,907090-FS1-10,While maximal exercise testing is useful for detection of arrhythmias and assessment of ANTIARRHYTHMIC DRUG EFFICACY few reports have documented the safety of this procedure in patients with malignant ventricular ARRHYTHMIAS.,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG EFFICACY,RO-may_prevent
503460491,7/16/2014 13:09:36,,1324245178,7/16/2014 13:09:18,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,no_relation,72,154,,92,166,treats,0.970494958830946,907030-FS1-2,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX,RO-may_prevent
503460491,7/16/2014 13:16:41,,1324248032,7/16/2014 13:16:18,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,72,154,,92,166,treats,0.970494958830946,907030-FS1-2,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX,RO-may_prevent
503460491,7/16/2014 13:25:04,,1324251364,7/16/2014 13:24:48,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,72,154,,92,166,treats,0.970494958830946,907030-FS1-2,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX,RO-may_prevent
503460491,7/16/2014 13:33:23,,1324255066,7/16/2014 13:32:52,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,72,154,,92,166,treats,0.970494958830946,907030-FS1-2,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX,RO-may_prevent
503460491,7/16/2014 14:16:41,,1324272152,7/16/2014 14:16:20,instagc,0.7677,28301350,GBR,K4,Plymouth,92.28.208.109,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,72,154,,92,166,treats,0.970494958830946,907030-FS1-2,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX,RO-may_prevent
503460491,7/16/2014 14:54:22,,1324285797,7/16/2014 14:53:58,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,THROMBOEMBOLIC EVENTS treats FONDAPARINUX,72,154,,92,166,treats,0.970494958830946,907030-FS1-2,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX,RO-may_prevent
503460491,7/16/2014 16:39:49,,1324330524,7/16/2014 16:39:26,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,FONDAPARINUX treats THROMBOEMBOLIC EVENTS,72,154,,92,166,treats,0.970494958830946,907030-FS1-2,"In the trial based analysis, fondaparinux was estimated to prevent 15.1 THROMBOEMBOLIC EVENTS per 1000 patients at three months compared with enoxaparin; FONDAPARINUX produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",THROMBOEMBOLIC EVENTS,FONDAPARINUX,RO-may_prevent
503460492,7/16/2014 13:12:03,,1324246132,7/16/2014 13:11:53,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,RISPERIDONE causes SCHIZOPHRENIA,104,0,,116,11,causes,0.341881729378914,907998-FS1-4,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460492,7/16/2014 13:19:34,,1324249148,7/16/2014 13:19:24,neodev,0.7306,25224036,CAN,ON,Sudbury,67.204.218.187,SCHIZOPHRENIA causes RISPERIDONE,104,0,,116,11,causes,0.341881729378914,907998-FS1-4,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460492,7/16/2014 13:21:51,,1324250080,7/16/2014 13:21:39,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,no_relation,104,0,,116,11,causes,0.341881729378914,907998-FS1-4,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460492,7/16/2014 13:29:24,,1324253240,7/16/2014 13:28:25,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,no_relation,104,0,,116,11,causes,0.341881729378914,907998-FS1-4,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460492,7/16/2014 13:31:53,,1324254413,7/16/2014 13:30:26,inboxpounds,0.65,22207998,GBR,N7,Banstead,86.3.88.5,no_relation,104,0,,116,11,causes,0.341881729378914,907998-FS1-4,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460492,7/16/2014 15:12:45,,1324292884,7/16/2014 15:12:27,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,RISPERIDONE causes SCHIZOPHRENIA,104,0,,116,11,causes,0.341881729378914,907998-FS1-4,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460492,7/16/2014 15:41:47,,1324302763,7/16/2014 15:41:25,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,no_relation,104,0,,116,11,causes,0.341881729378914,907998-FS1-4,RISPERIDONE is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of SCHIZOPHRENIA,SCHIZOPHRENIA,RISPERIDONE,RO-may_treat
503460493,7/16/2014 13:09:17,,1324245032,7/16/2014 13:08:55,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,72,105,,90,147,treats,0.983869910099907,907961-FS1-2,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN,RO-may_treat
503460493,7/16/2014 13:12:25,,1324246288,7/16/2014 13:11:55,instagc,0.7222,14378608,USA,NY,Brooklyn,24.189.101.95,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,72,105,,90,147,treats,0.983869910099907,907961-FS1-2,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN,RO-may_treat
503460493,7/16/2014 13:14:35,,1324247221,7/16/2014 13:14:09,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,72,105,,90,147,treats,0.983869910099907,907961-FS1-2,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN,RO-may_treat
503460493,7/16/2014 13:20:52,,1324249681,7/16/2014 13:20:33,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,72,105,,90,147,treats,0.983869910099907,907961-FS1-2,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN,RO-may_treat
503460493,7/16/2014 14:21:26,,1324274145,7/16/2014 14:20:34,fusioncash,0.6587,7012325,USA,CT,Stamford,24.185.182.15,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,72,105,,90,147,treats,0.983869910099907,907961-FS1-2,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN,RO-may_treat
503460493,7/16/2014 14:26:02,,1324275953,7/16/2014 14:25:39,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,72,105,,90,147,treats,0.983869910099907,907961-FS1-2,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN,RO-may_treat
503460493,7/16/2014 14:29:33,,1324277422,7/16/2014 14:29:08,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN treats BACTERIAL VAGINOSIS,72,105,,90,147,treats,0.983869910099907,907961-FS1-2,"Sobel JD, Schmitt C, Meriwether C. Long term follow up of patients with BACTERIAL VAGINOSIS treated with ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN.",BACTERIAL VAGINOSIS,ORAL METRONIDAZOLE AND TOPICAL CLINDAMYCIN,RO-may_treat
503460494,7/16/2014 13:20:31,,1324249498,7/16/2014 13:20:06,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,no_relation,91,63,,109,73,is location of,0.424264068711929,906133-FS1-9,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460494,7/16/2014 13:24:12,,1324250965,7/16/2014 13:23:29,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,BCL 2 GENE is location of FOLLICULAR LYMPHOMA,91,63,,109,73,is location of,0.424264068711929,906133-FS1-9,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460494,7/16/2014 13:33:55,,1324255329,7/16/2014 13:33:25,clixsense,0.7708,6564572,USA,MI,Kalamazoo,173.46.248.170,BCL 2 GENE is location of FOLLICULAR LYMPHOMA,91,63,,109,73,is location of,0.424264068711929,906133-FS1-9,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460494,7/16/2014 15:50:03,,1324306236,7/16/2014 15:49:49,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,91,63,,109,73,is location of,0.424264068711929,906133-FS1-9,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460494,7/16/2014 16:37:59,,1324329370,7/16/2014 16:37:26,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,BCL 2 GENE is location of FOLLICULAR LYMPHOMA,91,63,,109,73,is location of,0.424264068711929,906133-FS1-9,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460494,7/16/2014 17:46:31,,1324363702,7/16/2014 17:45:39,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,no_relation,91,63,,109,73,is location of,0.424264068711929,906133-FS1-9,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460494,7/16/2014 18:00:01,,1324377894,7/16/2014 17:59:27,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,BCL 2 GENE is location of FOLLICULAR LYMPHOMA,91,63,,109,73,is location of,0.424264068711929,906133-FS1-9,This study expands the geographical map of the distribution of BCL 2 GENE rearrangement in FOLLICULAR LYMPHOMA patients in the Middle East region.,FOLLICULAR LYMPHOMA,BCL 2 GENE,RO-has_manifestation
503460495,7/16/2014 13:07:35,,1324244340,7/16/2014 13:07:09,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL LUNG CANCER (SCLC),66,119,,95,148,causes,0.961523947640823,901631-FS1-4,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC),RO-disease_has_finding
503460495,7/16/2014 13:25:30,,1324251559,7/16/2014 13:25:00,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,SMALL CELL LUNG CANCER (SCLC) causes NEUROENDOCRINE DIFFERENTIATION,66,119,,95,148,causes,0.961523947640823,901631-FS1-4,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC),RO-disease_has_finding
503460495,7/16/2014 13:33:56,,1324255337,7/16/2014 13:33:15,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,no_relation,66,119,,95,148,causes,0.961523947640823,901631-FS1-4,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC),RO-disease_has_finding
503460495,7/16/2014 14:55:11,,1324286101,7/16/2014 14:54:46,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,no_relation,66,119,,95,148,causes,0.961523947640823,901631-FS1-4,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC),RO-disease_has_finding
503460495,7/16/2014 15:40:41,,1324302244,7/16/2014 15:40:17,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,no_relation,66,119,,95,148,causes,0.961523947640823,901631-FS1-4,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC),RO-disease_has_finding
503460495,7/16/2014 17:20:29,,1324344476,7/16/2014 17:19:29,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,NEUROENDOCRINE DIFFERENTIATION causes SMALL CELL LUNG CANCER (SCLC),66,119,,95,148,causes,0.961523947640823,901631-FS1-4,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC),RO-disease_has_finding
503460495,7/16/2014 18:00:38,,1324378477,7/16/2014 18:00:03,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,SMALL CELL LUNG CANCER (SCLC) causes NEUROENDOCRINE DIFFERENTIATION,66,119,,95,148,causes,0.961523947640823,901631-FS1-4,"A radioimmunoassay for neuron specific enolase (NSE), a marker of NEUROENDOCRINE DIFFERENTIATION has been evaluated in SMALL CELL LUNG CANCER (SCLC).",NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER (SCLC),RO-disease_has_finding
503460496,7/16/2014 13:06:47,,1324244038,7/16/2014 13:06:27,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,no_relation,284,202,,310,215,causes,0.547722557505166,902514-FS1-4,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS,RO-disease_may_have_finding
503460496,7/16/2014 13:22:48,,1324250409,7/16/2014 13:22:23,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,no_relation,284,202,,310,215,causes,0.547722557505166,902514-FS1-4,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS,RO-disease_may_have_finding
503460496,7/16/2014 13:26:30,,1324252002,7/16/2014 13:26:04,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,no_relation,284,202,,310,215,causes,0.547722557505166,902514-FS1-4,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS,RO-disease_may_have_finding
503460496,7/16/2014 13:30:58,,1324253976,7/16/2014 13:30:20,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,MICROCALCIFICATION CLUSTERS causes IN SITU (DCIS,284,202,,310,215,causes,0.547722557505166,902514-FS1-4,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS,RO-disease_may_have_finding
503460496,7/16/2014 16:39:01,,1324330121,7/16/2014 16:38:39,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,no_relation,284,202,,310,215,causes,0.547722557505166,902514-FS1-4,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS,RO-disease_may_have_finding
503460496,7/16/2014 17:18:45,,1324344018,7/16/2014 17:17:45,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,IN SITU (DCIS causes MICROCALCIFICATION CLUSTERS,284,202,,310,215,causes,0.547722557505166,902514-FS1-4,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS,RO-disease_may_have_finding
503460496,7/16/2014 17:28:13,,1324348017,7/16/2014 17:27:09,clixsense,0.6583,25595227,CAN,SK,North Battleford,24.72.96.119,MICROCALCIFICATION CLUSTERS causes IN SITU (DCIS,284,202,,310,215,causes,0.547722557505166,902514-FS1-4,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma IN SITU (DCIS) where it has been shown that there is a strong correlation between MICROCALCIFICATION CLUSTERS and malignancy.",MICROCALCIFICATION CLUSTERS,IN SITU (DCIS,RO-disease_may_have_finding
503460497,7/16/2014 13:16:14,,1324247803,7/16/2014 13:15:51,prodege,0.7917,9525153,CAN,ON,Toronto,65.95.94.44,GANCICLOVIR treats CMV INFECTION,123,93,,135,104,treats,0.995893206467704,907219-FS1-2,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR,RO-may_prevent
503460497,7/16/2014 15:36:18,,1324300476,7/16/2014 15:35:51,instagc,0.7538,19636746,USA,NY,Andover,192.182.216.225,GANCICLOVIR treats CMV INFECTION,123,93,,135,104,treats,0.995893206467704,907219-FS1-2,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR,RO-may_prevent
503460497,7/16/2014 15:37:07,,1324300776,7/16/2014 15:36:48,prodege,0.5498,23541832,USA,AZ,Tempe,149.169.143.104,no_relation,123,93,,135,104,treats,0.995893206467704,907219-FS1-2,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR,RO-may_prevent
503460497,7/16/2014 15:41:25,,1324302590,7/16/2014 15:40:41,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,GANCICLOVIR treats CMV INFECTION,123,93,,135,104,treats,0.995893206467704,907219-FS1-2,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR,RO-may_prevent
503460497,7/16/2014 16:37:24,,1324329001,7/16/2014 16:37:07,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,GANCICLOVIR treats CMV INFECTION,123,93,,135,104,treats,0.995893206467704,907219-FS1-2,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR,RO-may_prevent
503460497,7/16/2014 17:04:58,,1324339727,7/16/2014 17:04:54,prodege,0.4233,12944140,GBR,C8,Croydon,92.21.8.174,CMV INFECTION treats GANCICLOVIR,123,93,,135,104,treats,0.995893206467704,907219-FS1-2,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR,RO-may_prevent
503460497,7/16/2014 17:09:07,,1324341090,7/16/2014 17:08:43,clixsense,0.5952,19638651,USA,"","",173.23.121.63,GANCICLOVIR treats CMV INFECTION,123,93,,135,104,treats,0.995893206467704,907219-FS1-2,An example of AIDS research being helpful in the treatment of other conditions is the use of GANCICLOVIR for prevention of CMV INFECTION in transplant patients  who are vulnerable to infections because of the immune suppressive drugs they must take.,CMV INFECTION,GANCICLOVIR,RO-may_prevent
503460498,7/16/2014 13:05:49,,1324243652,7/16/2014 13:05:33,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,ANGINA PECTORIS causes PAIN,5,40,,8,55,causes,0.875189948987367,904812-FS1-4,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS,RO-has_definitional_manifestation
503460498,7/16/2014 13:34:39,,1324255686,7/16/2014 13:34:23,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,no_relation,5,40,,8,55,causes,0.875189948987367,904812-FS1-4,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS,RO-has_definitional_manifestation
503460498,7/16/2014 14:54:45,,1324285930,7/16/2014 14:54:22,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,no_relation,5,40,,8,55,causes,0.875189948987367,904812-FS1-4,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS,RO-has_definitional_manifestation
503460498,7/16/2014 15:40:41,,1324302243,7/16/2014 15:40:17,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,ANGINA PECTORIS causes PAIN,5,40,,8,55,causes,0.875189948987367,904812-FS1-4,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS,RO-has_definitional_manifestation
503460498,7/16/2014 16:57:26,,1324337244,7/16/2014 16:56:54,instagc,0.6306,14941596,USA,KY,Erlanger,74.140.124.145,ANGINA PECTORIS causes PAIN,5,40,,8,55,causes,0.875189948987367,904812-FS1-4,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS,RO-has_definitional_manifestation
503460498,7/16/2014 17:06:20,,1324340007,7/16/2014 17:06:14,prodege,0.4233,12944140,GBR,C8,Croydon,92.21.8.174,ANGINA PECTORIS causes PAIN,5,40,,8,55,causes,0.875189948987367,904812-FS1-4,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS,RO-has_definitional_manifestation
503460498,7/16/2014 17:09:07,,1324341091,7/16/2014 17:08:43,clixsense,0.5952,19638651,USA,"","",173.23.121.63,no_relation,5,40,,8,55,causes,0.875189948987367,904812-FS1-4,Such PAIN may be indistinguishable from ANGINA PECTORIS,PAIN,ANGINA PECTORIS,RO-has_definitional_manifestation
503460499,7/16/2014 13:18:55,,1324248918,7/16/2014 13:18:30,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,PHP IA causes ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),72,14,,111,20,causes,0.963086824686154,906061-FS1-4,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA,RO-has_manifestation
503460499,7/16/2014 13:34:22,,1324255527,7/16/2014 13:33:57,prodege,0.5958,1852770,USA,TX,Abilene,76.198.102.54,no_relation,72,14,,111,20,causes,0.963086824686154,906061-FS1-4,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA,RO-has_manifestation
503460499,7/16/2014 14:54:45,,1324285931,7/16/2014 14:54:22,prodege,0.505,28039757,GBR,L8,Southport,109.155.158.54,no_relation,72,14,,111,20,causes,0.963086824686154,906061-FS1-4,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA,RO-has_manifestation
503460499,7/16/2014 15:10:09,,1324292008,7/16/2014 15:10:02,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,PHP IA causes ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),72,14,,111,20,causes,0.963086824686154,906061-FS1-4,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA,RO-has_manifestation
503460499,7/16/2014 15:15:03,,1324293617,7/16/2014 15:14:50,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,PHP IA causes ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),72,14,,111,20,causes,0.963086824686154,906061-FS1-4,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA,RO-has_manifestation
503460499,7/16/2014 15:49:08,,1324305821,7/16/2014 15:48:58,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,no_relation,72,14,,111,20,causes,0.963086824686154,906061-FS1-4,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA,RO-has_manifestation
503460499,7/16/2014 16:39:25,,1324330320,7/16/2014 16:39:02,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,PHP IA causes ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),72,14,,111,20,causes,0.963086824686154,906061-FS1-4,"Patients with PHP IA exhibit a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO).",ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO),PHP IA,RO-has_manifestation
503460500,7/16/2014 13:05:49,,1324243648,7/16/2014 13:05:33,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,EPILEPSY causes SEIZURE,65,98,,71,106,causes,0.937042571331636,904589-FS1-4,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
503460500,7/16/2014 13:17:32,,1324248330,7/16/2014 13:16:42,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,EPILEPSY causes SEIZURE,65,98,,71,106,causes,0.937042571331636,904589-FS1-4,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
503460500,7/16/2014 13:19:50,,1324249255,7/16/2014 13:19:41,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,EPILEPSY causes SEIZURE,65,98,,71,106,causes,0.937042571331636,904589-FS1-4,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
503460500,7/16/2014 13:21:25,,1324249875,7/16/2014 13:21:14,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,EPILEPSY causes SEIZURE,65,98,,71,106,causes,0.937042571331636,904589-FS1-4,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
503460500,7/16/2014 13:33:43,,1324255239,7/16/2014 13:33:22,clixsense,0.7278,24896327,GBR,V2,Glasgow,94.2.231.4,EPILEPSY causes SEIZURE,65,98,,71,106,causes,0.937042571331636,904589-FS1-4,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
503460500,7/16/2014 13:50:44,,1324261408,7/16/2014 13:50:14,instagc,0.7333,13763729,USA,"","",75.182.89.225,EPILEPSY causes SEIZURE,65,98,,71,106,causes,0.937042571331636,904589-FS1-4,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
503460500,7/16/2014 14:26:27,,1324276088,7/16/2014 14:26:04,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,no_relation,65,98,,71,106,causes,0.937042571331636,904589-FS1-4,Treatment with antiepileptic drugs (AED) increases the chance of SEIZURE control in patients with EPILEPSY,SEIZURE,EPILEPSY,RO-has_definitional_manifestation
503460501,7/16/2014 13:22:18,,1324250271,7/16/2014 13:21:38,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,EDROPHONIUM (TENSILON) TEST diagnosed by MYASTHENIA GRAVIS,93,10,,109,37,diagnosed by,1,906604-FS1-13,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST,RO-may_diagnose
503460501,7/16/2014 13:50:44,,1324261409,7/16/2014 13:50:14,instagc,0.7333,13763729,USA,"","",75.182.89.225,MYASTHENIA GRAVIS diagnosed by EDROPHONIUM (TENSILON) TEST,93,10,,109,37,diagnosed by,1,906604-FS1-13,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST,RO-may_diagnose
503460501,7/16/2014 14:29:07,,1324277211,7/16/2014 14:28:28,vivatic,0.5899,25451531,GBR,"","",83.67.28.193,MYASTHENIA GRAVIS diagnosed by EDROPHONIUM (TENSILON) TEST,93,10,,109,37,diagnosed by,1,906604-FS1-13,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST,RO-may_diagnose
503460501,7/16/2014 17:04:38,,1324339609,7/16/2014 17:04:17,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,MYASTHENIA GRAVIS diagnosed by EDROPHONIUM (TENSILON) TEST,93,10,,109,37,diagnosed by,1,906604-FS1-13,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST,RO-may_diagnose
503460501,7/16/2014 17:17:43,,1324343760,7/16/2014 17:17:24,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,EDROPHONIUM (TENSILON) TEST diagnosed by MYASTHENIA GRAVIS,93,10,,109,37,diagnosed by,1,906604-FS1-13,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST,RO-may_diagnose
503460501,7/16/2014 18:07:59,,1324385884,7/16/2014 18:07:28,clixsense,0.4083,6451515,USA,MN,Minneapolis,75.144.36.177,MYASTHENIA GRAVIS diagnosed by EDROPHONIUM (TENSILON) TEST,93,10,,109,37,diagnosed by,1,906604-FS1-13,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST,RO-may_diagnose
503460501,7/16/2014 18:34:51,,1324404445,7/16/2014 18:34:41,instagc,0.4563,15445601,USA,FL,Jacksonville,24.129.68.254,MYASTHENIA GRAVIS diagnosed by EDROPHONIUM (TENSILON) TEST,93,10,,109,37,diagnosed by,1,906604-FS1-13,A bedside EDROPHONIUM (TENSILON) TEST in our emergency department confirmed the diagnosis of MYASTHENIA GRAVIS,MYASTHENIA GRAVIS,EDROPHONIUM (TENSILON) TEST,RO-may_diagnose
503460502,7/16/2014 13:19:14,,1324249011,7/16/2014 13:19:06,neodev,0.7833,25804244,USA,IL,Chicago,99.198.108.116,BACTERIA causes S PANAMA BACTEREMIA,32,71,,39,90,causes,0.730296743340221,903807-FS1-4,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460502,7/16/2014 15:02:09,,1324288887,7/16/2014 15:01:19,prodege,0.6956,17780691,CAN,ON,Toronto,24.114.226.82,BACTERIA causes S PANAMA BACTEREMIA,32,71,,39,90,causes,0.730296743340221,903807-FS1-4,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460502,7/16/2014 15:10:09,,1324292009,7/16/2014 15:10:02,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,BACTERIA causes S PANAMA BACTEREMIA,32,71,,39,90,causes,0.730296743340221,903807-FS1-4,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460502,7/16/2014 15:49:47,,1324306104,7/16/2014 15:49:31,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,BACTERIA causes S PANAMA BACTEREMIA,32,71,,39,90,causes,0.730296743340221,903807-FS1-4,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460502,7/16/2014 16:40:24,,1324330877,7/16/2014 16:40:11,neodev,0.5359,14861092,GBR,H9,London,90.194.156.173,no_relation,32,71,,39,90,causes,0.730296743340221,903807-FS1-4,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460502,7/16/2014 16:55:15,,1324336447,7/16/2014 16:54:24,clixsense,0.4786,6497991,USA,NC,Clinton,204.211.52.144,BACTERIA causes S PANAMA BACTEREMIA,32,71,,39,90,causes,0.730296743340221,903807-FS1-4,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460502,7/16/2014 17:04:59,,1324339732,7/16/2014 17:04:39,instagc,0.5901,23149109,USA,NC,Cary,24.206.38.18,S PANAMA BACTEREMIA causes BACTERIA,32,71,,39,90,causes,0.730296743340221,903807-FS1-4,"As to bacteriological efficacy, BACTERIA were reduced in the case with S PANAMA BACTEREMIA while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",BACTERIA,S PANAMA BACTEREMIA,RO-has_causative_agent
503460503,7/16/2014 13:07:37,,1324244348,7/16/2014 13:07:08,neodev,0.8194,18339121,USA,SC,Sumter,173.93.188.194,NICOTINE DEPENDENCE causes NICOTINE,33,33,,40,52,causes,0.975900072948533,903738-FS1-4,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE,RO-has_causative_agent
503460503,7/16/2014 13:20:31,,1324249497,7/16/2014 13:20:06,prodege,0.6875,22031444,GBR,B7,Bristol,77.98.139.82,NICOTINE causes NICOTINE DEPENDENCE,33,33,,40,52,causes,0.975900072948533,903738-FS1-4,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE,RO-has_causative_agent
503460503,7/16/2014 13:22:03,,1324250187,7/16/2014 13:21:53,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,NICOTINE causes NICOTINE DEPENDENCE,33,33,,40,52,causes,0.975900072948533,903738-FS1-4,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE,RO-has_causative_agent
503460503,7/16/2014 13:28:16,,1324252757,7/16/2014 13:27:29,rewardsspot,0.5306,24482174,GBR,H9,London,46.23.68.180,no_relation,33,33,,40,52,causes,0.975900072948533,903738-FS1-4,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE,RO-has_causative_agent
503460503,7/16/2014 15:40:15,,1324302082,7/16/2014 15:39:35,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,NICOTINE causes NICOTINE DEPENDENCE,33,33,,40,52,causes,0.975900072948533,903738-FS1-4,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE,RO-has_causative_agent
503460503,7/16/2014 17:06:12,,1324339965,7/16/2014 17:06:05,prodege,0.4233,12944140,GBR,C8,Croydon,92.21.8.174,NICOTINE causes NICOTINE DEPENDENCE,33,33,,40,52,causes,0.975900072948533,903738-FS1-4,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE,RO-has_causative_agent
503460503,7/16/2014 17:45:38,,1324362709,7/16/2014 17:45:10,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,NICOTINE causes NICOTINE DEPENDENCE,33,33,,40,52,causes,0.975900072948533,903738-FS1-4,An affective model suggests that NICOTINE DEPENDENCE should be related to an individual's tendency to experience negative affect and expectations that NICOTINE use would ameliorate such affect.,NICOTINE,NICOTINE DEPENDENCE,RO-has_causative_agent
503460504,7/16/2014 13:07:34,,1324244332,7/16/2014 13:07:18,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,ENDOMETRIOSIS causes PAIN,36,54,,39,67,causes,0.99654575824488,904760-FS1-4,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
503460504,7/16/2014 13:18:28,,1324248716,7/16/2014 13:18:13,elite,0.7917,28503042,USA,NJ,Woodbridge,54.191.150.115,ENDOMETRIOSIS causes PAIN,36,54,,39,67,causes,0.99654575824488,904760-FS1-4,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
503460504,7/16/2014 13:22:11,,1324250231,7/16/2014 13:22:05,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,ENDOMETRIOSIS causes PAIN,36,54,,39,67,causes,0.99654575824488,904760-FS1-4,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
503460504,7/16/2014 13:22:42,,1324250373,7/16/2014 13:22:14,neodev,0.6722,12115558,USA,OH,Twinsburg,75.187.196.41,ENDOMETRIOSIS causes PAIN,36,54,,39,67,causes,0.99654575824488,904760-FS1-4,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
503460504,7/16/2014 14:30:50,,1324278037,7/16/2014 14:30:32,clixsense,0.6486,17722340,CAN,BC,Mission,50.98.185.25,ENDOMETRIOSIS causes PAIN,36,54,,39,67,causes,0.99654575824488,904760-FS1-4,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
503460504,7/16/2014 15:14:24,,1324293438,7/16/2014 15:13:29,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,PAIN causes ENDOMETRIOSIS,36,54,,39,67,causes,0.99654575824488,904760-FS1-4,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
503460504,7/16/2014 15:39:35,,1324301792,7/16/2014 15:39:21,prodege,0.5256,15220325,USA,PA,Troy,24.229.175.37,ENDOMETRIOSIS causes PAIN,36,54,,39,67,causes,0.99654575824488,904760-FS1-4,The problem is determining when the PAIN is caused by ENDOMETRIOSIS,PAIN,ENDOMETRIOSIS,RO-has_definitional_manifestation
503460505,7/16/2014 13:08:20,,1324244705,7/16/2014 13:07:58,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,TUBERCULOSIS diagnosed by TUBERCULIN,91,44,,102,54,diagnosed by,0.927172649945531,906806-FS1-13,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
503460505,7/16/2014 13:11:35,,1324245933,7/16/2014 13:11:22,clixsense,0.9167,20614047,USA,MO,Maryville,174.32.162.147,TUBERCULOSIS diagnosed by TUBERCULIN,91,44,,102,54,diagnosed by,0.927172649945531,906806-FS1-13,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
503460505,7/16/2014 13:21:38,,1324249993,7/16/2014 13:21:26,clixsense,0.7208,27793793,GBR,C5,Chester,151.230.27.155,TUBERCULIN diagnosed by TUBERCULOSIS,91,44,,102,54,diagnosed by,0.927172649945531,906806-FS1-13,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
503460505,7/16/2014 17:20:29,,1324344477,7/16/2014 17:19:29,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,TUBERCULIN diagnosed by TUBERCULOSIS,91,44,,102,54,diagnosed by,0.927172649945531,906806-FS1-13,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
503460505,7/16/2014 17:46:31,,1324363701,7/16/2014 17:45:39,clixsense,0.6621,23398628,USA,WA,Spanaway,50.149.99.43,TUBERCULOSIS diagnosed by TUBERCULIN,91,44,,102,54,diagnosed by,0.927172649945531,906806-FS1-13,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
503460505,7/16/2014 18:00:38,,1324378478,7/16/2014 18:00:03,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,TUBERCULOSIS diagnosed by TUBERCULIN,91,44,,102,54,diagnosed by,0.927172649945531,906806-FS1-13,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
503460505,7/16/2014 18:23:20,,1324399335,7/16/2014 18:23:01,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,TUBERCULOSIS diagnosed by TUBERCULIN,91,44,,102,54,diagnosed by,0.927172649945531,906806-FS1-13,2 of 16 patients with kala azar tested with TUBERCULIN were positive; one was diagnosed as TUBERCULOSIS,TUBERCULOSIS,TUBERCULIN,RO-may_diagnose
503460506,7/16/2014 13:07:29,,1324244280,7/16/2014 13:06:41,prodege,0.9167,7664351,USA,NY,Cicero,74.111.0.21,no_relation,9,72,,48,93,causes,0.737209780774486,906332-FS1-4,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME,RO-has_manifestation
503460506,7/16/2014 15:09:41,,1324291855,7/16/2014 15:09:35,clixsense,0.6313,19162475,GBR,M3,Frome,82.33.126.30,PART OF WAGR SYNDROME causes MILD TO MODERATE INTELLECTUAL DISABILITY,9,72,,48,93,causes,0.737209780774486,906332-FS1-4,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME,RO-has_manifestation
503460506,7/16/2014 15:15:20,,1324293697,7/16/2014 15:15:05,elite,0.5194,28276268,USA,MI,Fenton,68.188.185.225,MILD TO MODERATE INTELLECTUAL DISABILITY causes PART OF WAGR SYNDROME,9,72,,48,93,causes,0.737209780774486,906332-FS1-4,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME,RO-has_manifestation
503460506,7/16/2014 15:48:34,,1324305632,7/16/2014 15:48:22,clixsense,0.58,16827630,GBR,A7,Birmingham,86.146.169.103,PART OF WAGR SYNDROME causes MILD TO MODERATE INTELLECTUAL DISABILITY,9,72,,48,93,causes,0.737209780774486,906332-FS1-4,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME,RO-has_manifestation
503460506,7/16/2014 16:52:48,,1324335612,7/16/2014 16:51:39,clixsense,0.4786,6497991,USA,NC,Clinton,204.211.52.144,MILD TO MODERATE INTELLECTUAL DISABILITY causes PART OF WAGR SYNDROME,9,72,,48,93,causes,0.737209780774486,906332-FS1-4,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME,RO-has_manifestation
503460506,7/16/2014 17:59:26,,1324377297,7/16/2014 17:58:50,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,PART OF WAGR SYNDROME causes MILD TO MODERATE INTELLECTUAL DISABILITY,9,72,,48,93,causes,0.737209780774486,906332-FS1-4,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME,RO-has_manifestation
503460506,7/16/2014 18:23:20,,1324399356,7/16/2014 18:23:01,gifthulk,0.6992,21916793,GBR,"","",87.113.87.199,PART OF WAGR SYNDROME causes MILD TO MODERATE INTELLECTUAL DISABILITY,9,72,,48,93,causes,0.737209780774486,906332-FS1-4,"Although MILD TO MODERATE INTELLECTUAL DISABILITY is usually considered PART OF WAGR SYNDROME (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",MILD TO MODERATE INTELLECTUAL DISABILITY,PART OF WAGR SYNDROME,RO-has_manifestation
503460507,7/16/2014 13:07:35,,1324244339,7/16/2014 13:07:09,clixsense,0.9583,27871219,NLD,07,Amsterdam,87.210.207.223,ALLERGY causes HYPERSENSITIVITY,102,182,,117,189,causes,0.437594974493684,900315-FS1-4,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460507,7/16/2014 13:09:36,,1324245180,7/16/2014 13:09:18,tremorgames,0.8889,24449707,CAN,QC,Laval,96.21.249.72,no_relation,102,182,,117,189,causes,0.437594974493684,900315-FS1-4,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460507,7/16/2014 13:22:18,,1324250273,7/16/2014 13:21:38,neodev,0.8806,21515166,NLD,11,Nootdorp,83.86.58.179,ALLERGY causes HYPERSENSITIVITY,102,182,,117,189,causes,0.437594974493684,900315-FS1-4,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460507,7/16/2014 14:25:14,,1324275636,7/16/2014 14:24:44,rewardsspot,0.6855,17763704,USA,VA,Manassas,198.7.62.204,ALLERGY causes HYPERSENSITIVITY,102,182,,117,189,causes,0.437594974493684,900315-FS1-4,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460507,7/16/2014 16:38:43,,1324329924,7/16/2014 16:38:19,prodege,0.5183,2143114,CAN,BC,Vancouver,24.84.160.12,HYPERSENSITIVITY causes ALLERGY,102,182,,117,189,causes,0.437594974493684,900315-FS1-4,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460507,7/16/2014 17:21:08,,1324344692,7/16/2014 17:20:30,prodege,0.521,19026375,GBR,Z1,Swansea,92.26.69.100,HYPERSENSITIVITY causes ALLERGY,102,182,,117,189,causes,0.437594974493684,900315-FS1-4,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
503460507,7/16/2014 18:01:28,,1324379264,7/16/2014 18:00:40,instagc,0.5512,28157545,USA,OR,Mcminnville,76.115.153.186,HYPERSENSITIVITY causes ALLERGY,102,182,,117,189,causes,0.437594974493684,900315-FS1-4,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, HYPERSENSITIVITY to thi antibiotic in the absence of clinical manifestations of ALLERGY was detected in 27% of children.",HYPERSENSITIVITY,ALLERGY,RO-cause_of
